Movatterモバイル変換

[0]ホーム
URL:

PT74434B - Continuous release pharmaceutical compositions - Google Patents

Continuous release pharmaceutical compositions

Info

Publication number
PT74434B
PT74434BPT74434APT7443482APT74434BPT 74434 BPT74434 BPT 74434BPT 74434 APT74434 APT 74434APT 7443482 APT7443482 APT 7443482APT 74434 BPT74434 BPT 74434B
Authority
PT
Portugal
Prior art keywords
pharmaceutical compositions
release pharmaceutical
continuous release
polylactides
release
Prior art date
Application number
PT74434A
Other languages
Portuguese (pt)
Other versions
PT74434A (en
Original Assignee
Ici Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=10519727&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT74434(B)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ici PlcfiledCriticalIci Plc
Publication of PT74434ApublicationCriticalpatent/PT74434A/en
Publication of PT74434BpublicationCriticalpatent/PT74434B/en

Links

Classifications

Landscapes

Abstract

Pharmaceutical compositions, comprising a polylactide and a pharmacologically active, acid stable polypeptide, which when placed in an aqueous physiological environment release the polypeptide at an approximately constant rate in an essentially monophasic manner, with a minimal, or no induction period prior to the release; polylactides suitable for use in said compositions; and a method for the manufacture of such polylactides.
PT74434A1981-02-161982-02-15Continuous release pharmaceutical compositionsPT74434B (en)

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
GB81047341981-02-16

Publications (2)

Publication NumberPublication Date
PT74434A PT74434A (en)1982-03-01
PT74434Btrue PT74434B (en)1983-07-14

Family

ID=10519727

Family Applications (1)

Application NumberTitlePriority DateFiling Date
PT74434APT74434B (en)1981-02-161982-02-15Continuous release pharmaceutical compositions

Country Status (20)

CountryLink
US (2)US5004602A (en)
EP (1)EP0058481B2 (en)
JP (4)JPS57150609A (en)
AT (1)ATE22535T1 (en)
AU (3)AU560829B2 (en)
CA (1)CA1169090A (en)
DE (1)DE3273501D1 (en)
DK (1)DK164845B (en)
ES (1)ES509647A0 (en)
FI (1)FI80594B (en)
GR (1)GR76791B (en)
HK (1)HK107890A (en)
HU (2)HU199695B (en)
IE (1)IE52535B1 (en)
MY (1)MY101545A (en)
NO (1)NO162103C (en)
NZ (1)NZ199732A (en)
PT (1)PT74434B (en)
YU (1)YU44066B (en)
ZA (1)ZA82565B (en)

Families Citing this family (1042)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
IE52535B1 (en)*1981-02-161987-12-09Ici PlcContinuous release pharmaceutical compositions
US4637905A (en)*1982-03-041987-01-20Batelle Development CorporationProcess of preparing microcapsules of lactides or lactide copolymers with glycolides and/or ε-caprolactones
FR2537980B1 (en)*1982-12-171986-12-19Sandoz Sa OLIGOMERIC HYDROXYCARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE
US4652443A (en)*1983-06-071987-03-24Japan Atomic Energy Research InstituteSlow-release composite and process for producing the same
CA1196864A (en)*1983-06-101985-11-19Mattheus F.A. GoosenControlled release of injectable and implantable insulin compositions
CH656884A5 (en)*1983-08-261986-07-31Sandoz Ag POLYOLESTERS, THEIR PRODUCTION AND USE.
CH661206A5 (en)*1983-09-231987-07-15Debiopharm Sa PROCESS FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF HORMONDEPENDENT DISEASES.
JPS6097918A (en)*1983-11-011985-05-31Sumitomo Chem Co Ltd Interferon long-acting preparation
JPS60100516A (en)*1983-11-041985-06-04Takeda Chem Ind LtdPreparation of sustained release microcapsule
JPS60181029A (en)*1984-02-291985-09-14Toyo Jozo Co LtdPreparation of sustained release preparation
GB8416234D0 (en)*1984-06-261984-08-01Ici PlcBiodegradable amphipathic copolymers
CA1256638A (en)*1984-07-061989-06-27Motoaki TanakaPolymer and its production
US4760053A (en)*1984-08-021988-07-26Fernand LabrieCombination therapy for selected sex steroid dependent cancers
US4666885A (en)*1985-02-081987-05-19Fernand LabrieCombination therapy for treatment of female breast cancer
US4880635B1 (en)*1984-08-081996-07-02Liposome CompanyDehydrated liposomes
DE3434345A1 (en)*1984-09-191986-03-27Hoechst Ag, 6230 Frankfurt USE OF (ALPHA) INTERFERONES TO COMBAT THROUGH
DE3678308D1 (en)*1985-02-071991-05-02Takeda Chemical Industries Ltd METHOD FOR PRODUCING MICROCAPSULES.
NZ216122A (en)*1985-05-101989-07-27Univ MelbourneStimulating ovulation in mares by administering gonadotrophin-releasing hormones
US5137874A (en)*1985-07-291992-08-11American Cyanamid Co.Partially coated C10 -C20 fatty acid salts of peptides having molecular weights up to about 5,000
US5169633A (en)*1985-07-291992-12-08American Cyanamid CompanyContinuous release phenylethanolamine derivative compositions
US5059422A (en)*1985-07-291991-10-22American Cyanamid CompanyContinuous release phenylethanolamine derivative compositions
US5102872A (en)*1985-09-201992-04-07Cetus CorporationControlled-release formulations of interleukin-2
US4643191A (en)*1985-11-291987-02-17Ethicon, Inc.Crystalline copolymers of p-dioxanone and lactide and surgical devices made therefrom
JPH0725688B2 (en)*1986-03-311995-03-22住友製薬株式会社 CSF sustained release formulation
GB8609537D0 (en)*1986-04-181986-05-21Ici PlcPolyesters
EP0248531A3 (en)*1986-05-021988-09-28Southern Research InstituteEncapsulated nucleic acids
CA1257199A (en)*1986-05-201989-07-11Paul Y. WangPreparation containing bioactive macromolecular substance for multi-months release in vivo
US4962091A (en)*1986-05-231990-10-09Syntex (U.S.A.) Inc.Controlled release of macromolecular polypeptides
US6150328A (en)1986-07-012000-11-21Genetics Institute, Inc.BMP products
JPH0725689B2 (en)*1986-10-071995-03-22中外製薬株式会社 Sustained-release preparation containing granulocyte colony-stimulating factor
US6024983A (en)*1986-10-242000-02-15Southern Research InstituteComposition for delivering bioactive agents for immune response and its preparation
US4981696A (en)*1986-12-221991-01-01E. I. Du Pont De Nemours And CompanyPolylactide compositions
DE3701625A1 (en)*1987-01-211988-08-04Boehringer Ingelheim Kg PERORAL DRUG PREPARATION WITH DELAYED ACTIVE RELEASE
DE3710175A1 (en)*1987-02-121988-08-25Hoechst Ag MULTI-PIECE IMPLANTABLE MEDICINE PREPARATION WITH LONG-TERM EFFECT
AU606383B2 (en)*1987-03-061991-02-07Research Triangle InstitutePolymer blends for selective biodegradability
US5028430A (en)*1987-05-081991-07-02Syntex (U.S.A.) Inc.Delivery systems for the controlled administration of LHRH analogs
US5000886A (en)*1987-05-261991-03-19American Cyanamid CompanySilicone-hardened pharmaceutical microcapsules and process of making the same
GB8716324D0 (en)*1987-07-101987-08-19Sandoz LtdOrganic compounds
DE3822557C2 (en)*1987-07-101998-07-02Ciba Geigy Ag Medicines containing somatostatins
US4866226A (en)*1987-07-131989-09-12Mitsubishi Denki Kabushiki KaishaMulti-phase circuit breaker employing arc extinguishing apparatus
JPH0613602B2 (en)*1987-07-141994-02-23三井東圧化学株式会社 Method for producing d-l-lactic acid-glycolic acid copolymer
US4897268A (en)*1987-08-031990-01-30Southern Research InstituteDrug delivery system and method of making the same
US5212154A (en)*1987-08-141993-05-18Akzo N.V.Preparation for treating complications in diabetes
NZ226171A (en)*1987-09-181990-06-26Ethicon IncGel formulation containing polypeptide growth factor
US5457093A (en)*1987-09-181995-10-10Ethicon, Inc.Gel formulations containing growth factors
GB2209937B (en)*1987-09-211991-07-03Depiopharm S AWater insoluble polypeptides
US5187150A (en)*1987-10-141993-02-16Debiopharm S.A.Polyester-based composition for the controlled release of polypeptide medicinal substances
JP2670680B2 (en)*1988-02-241997-10-29株式会社ビーエムジー Polylactic acid microspheres containing physiologically active substance and method for producing the same
US4902515A (en)*1988-04-281990-02-20E. I. Dupont De Nemours And CompanyPolylactide compositions
FR2634770B1 (en)*1988-07-291990-10-05Rhone Poulenc Chimie EODABLE POLYESTER COMPOSITION CONTAINING IODINE FOR WATER TREATMENT
US6323307B1 (en)1988-08-082001-11-27Cargill Dow Polymers, LlcDegradation control of environmentally degradable disposable materials
US5180765A (en)*1988-08-081993-01-19Biopak Technology, Ltd.Biodegradable packaging thermoplastics from lactides
US5502158A (en)*1988-08-081996-03-26Ecopol, LlcDegradable polymer composition
US5424346A (en)*1988-08-081995-06-13Ecopol, LlcBiodegradable replacement of crystal polystyrene
US5252642A (en)*1989-03-011993-10-12Biopak Technology, Ltd.Degradable impact modified polyactic acid
US5444113A (en)*1988-08-081995-08-22Ecopol, LlcEnd use applications of biodegradable polymers
US5216050A (en)*1988-08-081993-06-01Biopak Technology, Ltd.Blends of polyactic acid
US5250584A (en)*1988-08-311993-10-05G-C Dental Industrial Corp.Periodontium-regenerative materials
US5633002A (en)*1988-10-041997-05-27Boehringer Ingelheim GmbhImplantable, biodegradable system for releasing active substance
US5247013A (en)*1989-01-271993-09-21Mitsui Toatsu Chemicals, Inc.Biocompatible polyester and production thereof
US4990336A (en)*1989-02-081991-02-05Biosearch, Inc.Sustained release dosage form
US5116964A (en)1989-02-231992-05-26Genentech, Inc.Hybrid immunoglobulins
ZA901847B (en)*1989-03-101991-10-30Endorecherche IncCombination therapy for the treatment of estrogen sensitive diseases
NZ234227A (en)*1989-06-301991-08-27Smithkline Beecham CorpDelayed release dosage form
US5538739A (en)*1989-07-071996-07-23Sandoz Ltd.Sustained release formulations of water soluble peptides
HUT60280A (en)*1989-07-071992-08-28Endorecherche IncProcess for producing androgen derivatives inhibiting sexual steroidal activity, as well as pharmaceutical compositions comprising same
HU221294B1 (en)*1989-07-072002-09-28Novartis AgProcess for producing retarde compositions containing the active ingredient in a polymeric carrier
PH30995A (en)*1989-07-071997-12-23Novartis IncSustained release formulations of water soluble peptides.
HUT60139A (en)*1989-07-071992-08-28Endorecherche IncProcess for producing pharmaceutical composition suitable for treating prostate cancer connected with androgen
CH679207A5 (en)*1989-07-281992-01-15Debiopharm Sa
US5439688A (en)*1989-07-281995-08-08Debio Recherche Pharmaceutique S.A.Process for preparing a pharmaceutical composition
US5225205A (en)*1989-07-281993-07-06Debiopharm S.A.Pharmaceutical composition in the form of microparticles
DE59003337D1 (en)*1989-10-161993-12-09Danubia Petrochem Polymere Pressling with delayed release of active ingredient.
US5126147A (en)*1990-02-081992-06-30Biosearch, Inc.Sustained release dosage form
US6517859B1 (en)1990-05-162003-02-11Southern Research InstituteMicrocapsules for administration of neuroactive agents
ATE226091T1 (en)*1990-05-162002-11-15Southern Res Inst CONTROLLED RELEASE MICROCAPSULES AND THEIR USE FOR STIMULATING NERVE FIBER GROWTH
CA2046830C (en)*1990-07-191999-12-14Patrick P. DelucaDrug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
IE912365A1 (en)*1990-07-231992-01-29Zeneca LtdContinuous release pharmaceutical compositions
US5620959A (en)*1990-07-311997-04-15Glaxo Wellcome Inc.Bombesin antagonists
GB9016885D0 (en)*1990-08-011990-09-12ScrasSustained release pharmaceutical compositions
US6353030B1 (en)1990-08-012002-03-05Novartis AgRelating to organic compounds
ZA918168B (en)*1990-10-161993-04-14Takeda Chemical Industries LtdProlonged release preparation and polymers thereof.
US5342557A (en)*1990-11-271994-08-30United States Surgical CorporationProcess for preparing polymer particles
US7285531B1 (en)*1991-04-102007-10-23Acorda Therapeutics, Inc.Method for prophylaxis or treatment of a nervous system, pathophysiological condition involving a glial growth factor sensitive cell by administration of a glial growth factor
US5486362A (en)*1991-05-071996-01-23Dynagen, Inc.Controlled, sustained release delivery system for treating drug dependency
US5403595A (en)*1991-05-071995-04-04Dynagen, Inc.Controlled, sustained release delivery system for smoking cessation
HU222501B1 (en)*1991-06-282003-07-28Endorecherche Inc. For the preparation of a sustained release pharmaceutical composition and method comprising MPA or MGA
ZA924811B (en)*1991-06-281993-12-29Endorecherche IncControlled release systems and low dose androgens
CH683149A5 (en)*1991-07-221994-01-31Debio Rech Pharma SaProcess for the preparation of microspheres of a biodegradable polymeric material.
AU674500B2 (en)1991-11-041997-01-02Genetics Institute, LlcRecombinant bone morphogenetic protein heterodimers, compositions and methods of use
US5876452A (en)*1992-02-141999-03-02Board Of Regents, University Of Texas SystemBiodegradable implant
US6013853A (en)*1992-02-142000-01-11The University Of Texas SystemContinuous release polymeric implant carrier
US5912015A (en)1992-03-121999-06-15Alkermes Controlled Therapeutics, Inc.Modulated release from biocompatible polymers
CA2129514A1 (en)*1992-03-121993-09-16M. Amin KhanControlled released acth containing microspheres
US5656297A (en)*1992-03-121997-08-12Alkermes Controlled Therapeutics, IncorporatedModulated release from biocompatible polymers
US5429822A (en)*1992-03-131995-07-04Cambridge Scientific, Inc.Biodegradable bursting release system
US5780051A (en)*1992-04-021998-07-14Dynagen, Inc.Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
JPH07506575A (en)*1992-05-211995-07-20アンドルシェルシュ・インコーポレイテッド Inhibitor of testosterone 5α-reductase activity
GB9211268D0 (en)*1992-05-281992-07-15Ici PlcSalts of basic peptides with carboxyterminated polyesters
US5674534A (en)*1992-06-111997-10-07Alkermes, Inc.Composition for sustained release of non-aggregated erythropoietin
US5716644A (en)*1992-06-111998-02-10Alkermes, Inc.Composition for sustained release of non-aggregated erythropoietin
US20030035845A1 (en)*1992-06-112003-02-20Zale Stephen E.Composition for sustained release of non-aggregated erythropoietin
JP2651320B2 (en)*1992-07-161997-09-10田辺製薬株式会社 Method for producing sustained-release microsphere preparation
FR2693905B1 (en)*1992-07-271994-09-02Rhone Merieux Process for the preparation of microspheres for the sustained release of the hormone LHRH and its analogs, microspheres and formulations obtained.
US5922340A (en)*1992-09-101999-07-13Children's Medical Center CorporationHigh load formulations and methods for providing prolonged local anesthesia
US5281419A (en)*1992-09-281994-01-25Thomas Jefferson UniversityBiodegradable drug delivery system for the prevention and treatment of osteomyelitis
AU670168B2 (en)*1992-12-021996-07-04Alkermes Controlled Therapeutics, Inc.Controlled release growth hormone containing microspheres
UA61046C2 (en)1992-12-072003-11-17Takeda Chemical Industries LtdSustained-release preparation and method for its manufacture
TW333456B (en)*1992-12-071998-06-11Takeda Pharm Ind Co LtdA pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5863985A (en)*1995-06-291999-01-26Kinerton LimitedIonic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5672659A (en)*1993-01-061997-09-30Kinerton LimitedIonic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US6221958B1 (en)1993-01-062001-04-24Societe De Conseils De Recherches Et D'applications Scientifiques, SasIonic molecular conjugates of biodegradable polyesters and bioactive polypeptides
HU220137B (en)*1993-01-062001-11-28Kinerton Ltd. Ionic molecular conjugates of biodegradable polyesters and biologically active polypeptides, a process for their preparation and a method for producing microparticles
US5456917A (en)*1993-04-121995-10-10Cambridge Scientific, Inc.Method for making a bioerodible material for the sustained release of a medicament and the material made from the method
US5569467A (en)*1993-05-151996-10-29Societe De Conseils De Recherches Et D'applications (S.C.R.A.S.)Process for the preparation of microballs and microballs thus obtained
GB9310030D0 (en)*1993-05-151993-06-30ScrasDry processed particles and process for the preparation of the same
US6440457B1 (en)1993-05-272002-08-27Alza CorporationMethod of administering antidepressant dosage form
US5635216A (en)*1993-12-161997-06-03Eli Lilly And CompanyMicroparticle compositions containing peptides, and methods for the preparation thereof
DE69407292T2 (en)*1993-06-301998-06-25Genentech Inc METHOD FOR PRODUCING LIPOSOME
CA2170641C (en)1993-08-302011-11-15James R. SmithSenescent cell-derived inhibitors of dna synthesis
US6291206B1 (en)1993-09-172001-09-18Genetics Institute, Inc.BMP receptor proteins
US5496923A (en)*1993-09-201996-03-05Mitsui Toatsu Chemicals, Inc.Purification process of aliphatic polyester
US5643605A (en)*1993-10-251997-07-01Genentech, Inc.Methods and compositions for microencapsulation of adjuvants
US6913767B1 (en)1993-10-252005-07-05Genentech, Inc.Compositions for microencapsulation of antigens for use as vaccines
US6080429A (en)*1993-10-252000-06-27Genentech, Inc.Method for drying microspheres
CA2176942C (en)1993-12-072011-11-01Anthony J. CelesteBmp-12, bmp-13 and tendon-inducing compositions thereof
US6074840A (en)*1994-02-182000-06-13The Regents Of The University Of MichiganRecombinant production of latent TGF-beta binding protein-3 (LTBP-3)
US20020193338A1 (en)*1994-02-182002-12-19Goldstein Steven A.In vivo gene transfer methods for wound healing
US5942496A (en)*1994-02-181999-08-24The Regent Of The University Of MichiganMethods and compositions for multiple gene transfer into bone cells
US5763416A (en)*1994-02-181998-06-09The Regent Of The University Of MichiganGene transfer into bone cells and tissues
US5962427A (en)*1994-02-181999-10-05The Regent Of The University Of MichiganIn vivo gene transfer methods for wound healing
DE4406172C2 (en)*1994-02-252003-10-02Sanol Arznei Schwarz Gmbh polyester
US6551618B2 (en)*1994-03-152003-04-22University Of BirminghamCompositions and methods for delivery of agents for neuronal regeneration and survival
US5877016A (en)1994-03-181999-03-02Genentech, Inc.Human trk receptors and neurotrophic factor inhibitors
US5708142A (en)1994-05-271998-01-13Genentech, Inc.Tumor necrosis factor receptor-associated factors
GB9412273D0 (en)1994-06-181994-08-10Univ NottinghamAdministration means
US6093697A (en)*1994-11-072000-07-25The University Of Virginia Patent FoundationSynthetic insulin mimetic substances
US5607686A (en)*1994-11-221997-03-04United States Surgical CorporationPolymeric composition
JPH11501027A (en)*1995-02-281999-01-26イナファーマ，インコーポレイテッド Elcatonin controlled release microsphere formulations for treatment of osteoporosis
US5665702A (en)*1995-06-061997-09-09Biomeasure IncorporatedIonic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US6479457B2 (en)1995-06-062002-11-12Kinerton LimitedIonic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US6413536B1 (en)1995-06-072002-07-02Southern Biosystems, Inc.High viscosity liquid controlled delivery system and medical or surgical device
US5747058A (en)*1995-06-071998-05-05Southern Biosystems, Inc.High viscosity liquid controlled delivery system
US5674888A (en)*1995-06-071997-10-07University Of CaliforniaMethod for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
US7833543B2 (en)*1995-06-072010-11-16Durect CorporationHigh viscosity liquid controlled delivery system and medical or surgical device
US5599535A (en)*1995-06-071997-02-04Regents Of The University Of CaliforniaMethods for the cyto-protection of the trabecular meshwork
US5968542A (en)*1995-06-071999-10-19Southern Biosystems, Inc.High viscosity liquid controlled delivery system as a device
WO1996041616A1 (en)*1995-06-091996-12-27Euro-Celtique, S.A.Formulations and methods for providing prolonged local anesthesia
US5955574A (en)1995-07-131999-09-21Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.Analogs of parathyroid hormone
US5925351A (en)1995-07-211999-07-20Biogen, Inc.Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6020473A (en)*1995-08-252000-02-01Genentech, Inc.Nucleic acids encoding variants of vascular endothelial cell growth factor
US7005505B1 (en)1995-08-252006-02-28Genentech, Inc.Variants of vascular endothelial cell growth factor
EP0789045B1 (en)*1995-08-292001-01-10Kyowa Hakko Kogyo Co., Ltd.Process for producing polyhydroxy carboxylic acid
AU710347B2 (en)*1995-08-311999-09-16Alkermes Controlled Therapeutics, Inc.Composition for sustained release of an agent
US5942253A (en)*1995-10-121999-08-24Immunex CorporationProlonged release of GM-CSF
CA2192773C (en)1995-12-152008-09-23Hiroaki OkadaProduction of sustained-release preparation for injection
US5980945A (en)*1996-01-161999-11-09Societe De Conseils De Recherches Et D'applications Scientifique S.A.Sustained release drug formulations
WO1997031049A1 (en)*1996-02-231997-08-28Kyowa Hakko Kogyo Co., Ltd.Process for the preparation of polyhydroxycarboxylic acid
US5747060A (en)*1996-03-261998-05-05Euro-Celtique, S.A.Prolonged local anesthesia with colchicine
PL329598A1 (en)*1996-04-231999-03-29Kinerton LtdAcidic lactic acid polymers
IE960308A1 (en)*1996-04-231997-11-05Kinerton LtdSustained release ionic conjugate
US6100071A (en)1996-05-072000-08-08Genentech, Inc.Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US5766877A (en)*1996-05-101998-06-16Amgen Inc.Genes encoding art, an agouti-related transcript
US5817343A (en)*1996-05-141998-10-06Alkermes, Inc.Method for fabricating polymer-based controlled-release devices
AU733867B2 (en)1996-06-242001-05-31Euro-Celtique S.A.Methods for providing safe local anesthesia
US6046187A (en)1996-09-162000-04-04Children's Medical Center CorporationFormulations and methods for providing prolonged local anesthesia
US5952455A (en)*1996-10-111999-09-14Kyowa Hakko Kogyo Co., Ltd.Process for producing polyhydroxycarboxylic acid
DE69635088T3 (en)1996-10-252012-01-26Human Genome Sciences, Inc. NEUTROKIN alpha
DE69730093T2 (en)1996-10-312006-07-20Takeda Pharmaceutical Co. Ltd. Preparation with delayed release
US6593290B1 (en)1996-11-012003-07-15Genentech, Inc.Treatment of inner ear hair cells
US6156728A (en)*1996-11-012000-12-05Genentech, Inc.Treatment of inner ear hair cells
US6919373B1 (en)1996-11-122005-07-19Alza CorporationMethods and devices for providing prolonged drug therapy
US7390891B1 (en)1996-11-152008-06-24Amgen Inc.Polynucleotides encoding a telomerase component TP2
US5919656A (en)*1996-11-151999-07-06Amgen Canada Inc.Genes encoding telomerase protein 1
US20020111603A1 (en)1996-12-022002-08-15Societe De Conseils De Recherches Et D'applicationDevice for local administration of solid or semi-solid formulations and delayed-release formulations for proposal parental administration and preparation process
US7138511B1 (en)1997-01-282006-11-21The Regents Of The University Of CaliforniaNucleic acids, kits and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US6475724B1 (en)1997-01-282002-11-05The Regents Of The University Of CaliforniaNucleic acids, kits, and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US6171788B1 (en)1997-01-282001-01-09The Regents Of The University Of CaliforniaMethods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US7235524B2 (en)*1997-01-312007-06-26Applied Research System Ars Holding N.V.Medicaments for initiating ovulation
US5945126A (en)*1997-02-131999-08-31Oakwood Laboratories L.L.C.Continuous microsphere process
US6071982A (en)*1997-04-182000-06-06Cambridge Scientific, Inc.Bioerodible polymeric semi-interpenetrating network alloys for surgical plates and bone cements, and method for making same
US20060025328A1 (en)*1997-05-282006-02-02Burns Patrick JCompositions suitable for controlled release of the hormone GnRH and its analogs
EP1015477B1 (en)1997-05-302010-11-10Human Genome Sciences, Inc.32 Human secreted proteins
US6867181B1 (en)1997-06-022005-03-15Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S.Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US6663899B2 (en)1997-06-132003-12-16Genentech, Inc.Controlled release microencapsulated NGF formulation
US6113947A (en)*1997-06-132000-09-05Genentech, Inc.Controlled release microencapsulated NGF formulation
CA2271750C (en)1997-07-022004-04-27Euro-Celtique, S.A.Prolonged anesthesia in joints and body spaces
US6977074B2 (en)*1997-07-102005-12-20Mannkind CorporationMethod of inducing a CTL response
US6994851B1 (en)1997-07-102006-02-07Mannkind CorporationMethod of inducing a CTL response
WO1999006563A1 (en)1997-07-301999-02-11Emory UniversityNovel bone mineralization proteins, dna, vectors, expression systems
US7923250B2 (en)1997-07-302011-04-12Warsaw Orthopedic, Inc.Methods of expressing LIM mineralization protein in non-osseous cells
US6342220B1 (en)1997-08-252002-01-29Genentech, Inc.Agonist antibodies
ES2333385T3 (en)1997-09-172010-02-19Human Genome Sciences, Inc. PROTEIN OF THE INTERLEUQUINE TYPE-17.
WO1999024061A1 (en)1997-11-071999-05-20Chiron CorporationMethod for producing igf-1 sustained-release formulations
US6372880B1 (en)1997-12-252002-04-16Mitsui Chemicals, Inc.Copolymer and process for preparing the same
US5906979A (en)*1998-01-271999-05-25Insmed Pharmaceuticals, Inc.Compositions and methods for treating metabolic diseases characterized by hyperandrogenism and/or anovulation and/or infertility
DK1053020T3 (en)*1998-01-292004-07-26Poly Med Inc Absorbable microparticles
AR014069A1 (en)1998-01-292001-01-31Kinerton Ltd PROCEDURE FOR PREPARING MICROPARTICLE OR UNITED MICROPARTICLES ENCAPSULATED
NZ525914A (en)1998-03-102004-03-26Genentech IncNovel polypeptides and nucleic acids encoding the same
US20030180368A1 (en)*1998-03-142003-09-25Cenes Drug Delivery LimitedProduction of microparticles
IL138488A0 (en)1998-03-172001-10-31Genentech IncPolypeptides homologous to vegf and bmp1
EP1982990A1 (en)1998-03-192008-10-22Human Genome Sciences, Inc.Cytokine receptor common gamma chain like
AR020650A1 (en)*1998-08-102002-05-22Poly Med Inc PHOSPHORILED AND CONJUGATED POLYMERS OF THE SAME
US7662409B2 (en)*1998-09-252010-02-16Gel-Del Technologies, Inc.Protein matrix materials, devices and methods of making and using thereof
US20030007991A1 (en)*1998-09-252003-01-09Masters David B.Devices including protein matrix materials and methods of making and using thereof
US6344541B1 (en)1998-09-252002-02-05Amgen Inc.DKR polypeptides
TR200100974T2 (en)1998-10-092001-11-21Biogen, Inc. Systematic shock and respiratory distress caused by virus rejection by blocking the lymphotoxin beta pathway
US6143314A (en)*1998-10-282000-11-07Atrix Laboratories, Inc.Controlled release liquid delivery compositions with low initial drug burst
US6270802B1 (en)1998-10-282001-08-07Oakwood Laboratories L.L.C.Method and apparatus for formulating microspheres and microcapsules
US6565874B1 (en)*1998-10-282003-05-20Atrix LaboratoriesPolymeric delivery formulations of leuprolide with improved efficacy
EP1144013B1 (en)1998-11-022007-03-21Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S.Lactone bearing absorbable polymers
AUPP785098A0 (en)1998-12-211999-01-21Victor Chang Cardiac Research Institute, TheTreatment of heart disease
US6365173B1 (en)1999-01-142002-04-02Efrat Biopolymers Ltd.Stereocomplex polymeric carriers for drug delivery
US6303749B1 (en)1999-01-292001-10-16Amgen Inc.Agouti and agouti-related peptide analogs
US6727224B1 (en)1999-02-012004-04-27Genetics Institute, Llc.Methods and compositions for healing and repair of articular cartilage
US8624010B1 (en)1999-02-032014-01-07Steven K. YoshinagaNucleic acids encoding B7RP1
US7435796B1 (en)1999-02-032008-10-14Amgen Inc.Antibodies which bind B7RP1
US7708993B2 (en)1999-02-032010-05-04Amgen Inc.Polypeptides involved in immune response
PT2332976E (en)1999-02-032014-05-23Amgen IncNovel polypeptides involved in immune response
JP2002537102A (en)1999-02-262002-11-05カイロン コーポレイション Microemulsion with adsorbed polymer and fine particles
CA2363779A1 (en)1999-02-262000-08-31Human Genome Sciences, Inc.Human endokine alpha and methods of use
WO2000054797A2 (en)1999-03-172000-09-21Novartis AgPharmaceutical compositions comprising tgf-beta
WO2000058479A1 (en)1999-03-262000-10-05Amgen Inc.Beta secretase genes and polypeptides
US6635249B1 (en)1999-04-232003-10-21Cenes Pharmaceuticals, Inc.Methods for treating congestive heart failure
US20030166561A1 (en)*1999-06-182003-09-04Cooper Garth J. S.Peptide
CN100526463C (en)1999-06-282009-08-12杰南技术公司Method for preparing Apo-2 ligand by using divalent metal ions
US7713739B1 (en)2000-11-172010-05-11Novartis Vaccines And Diagnostics, Inc.Microparticle-based transfection and activation of dendritic cells
US7459540B1 (en)1999-09-072008-12-02Amgen Inc.Fibroblast growth factor-like polypeptides
US7408047B1 (en)1999-09-072008-08-05Amgen Inc.Fibroblast growth factor-like polypeptides
PT1223990E (en)1999-10-152004-12-31Fidia Advanced Biopolymers Srl HYALURONIC ACID FORMULATIONS FOR ADMINISTRATION OF OSTEOGENIC PROTEINS
US7078382B1 (en)1999-11-022006-07-18Genentech, Inc.Modulation of eNOS activity and therapeutic uses thereof
US6682754B2 (en)*1999-11-242004-01-27Willmar Poultry Company, Inc.Ovo delivery of an immunogen containing implant
US6465425B1 (en)*2000-02-102002-10-15Alkermes Controlled Therapeutics, Inc.Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US20030103978A1 (en)2000-02-232003-06-05Amgen Inc.Selective binding agents of osteoprotegerin binding protein
EP1265630B1 (en)*2000-03-242006-06-07Genentech, Inc.Use of insulin for the treatment of cartilagenous disorders
US7514239B2 (en)2000-03-282009-04-07Amgen Inc.Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
JP2003530838A (en)2000-04-122003-10-21ヒューマン ゲノム サイエンシズ インコーポレイテッド Albumin fusion protein
AU6342101A (en)*2000-05-242001-12-03Jordan Loyal HoltzmanAgents and methods for increasing brain chaperonin levels
US20040033241A1 (en)*2000-06-022004-02-19Allergan, Inc.Controlled release botulinum toxin system
US20040170665A1 (en)*2000-06-022004-09-02Allergan, Inc.Intravitreal botulinum toxin implant
US6306423B1 (en)2000-06-022001-10-23Allergan Sales, Inc.Neurotoxin implant
EP2431054A3 (en)2000-06-152013-03-06Human Genome Sciences, Inc.Human tumor necrosis factor delta and epsilon
CA2709771A1 (en)2000-06-232002-01-03Genentech, Inc.Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
DK2042597T3 (en)2000-06-232014-08-11Genentech Inc COMPOSITIONS AND PROCEDURES FOR DIAGNOSIS AND TREATMENT OF DISEASES INVOLVING ANGIOGENESIS
ES2391124T3 (en)2000-06-282012-11-21Amgen Inc. Thymic stromal lymphopoietin receptor molecules and uses thereof
ES2256276T5 (en)2000-08-072011-02-22Wako Pure Chemical Industries, Ltd. LACTIC ACID POLYMER AND PROCEDURE FOR PRODUCTION.
US6362308B1 (en)*2000-08-102002-03-26Alkermes Controlled Therapeutics Inc. IiAcid end group poly(d,l-lactide-co-glycolide) copolymers high glycolide content
US6565888B1 (en)2000-08-232003-05-20Alkermes Controlled Therapeutics, Inc.Methods and compositions for the targeted delivery of biologically active agents
AU8901901A (en)2000-09-142002-03-26Biogen IncTweak receptor agonists as anti-angiogenic agents background
CA2423431A1 (en)*2000-10-062002-04-11Durect CorporationDevices and methods for management of inflammation
DE10055742B4 (en)2000-11-102006-05-11Schwarz Pharma Ag New polyesters, processes for their preparation and depot dosage forms prepared from the polyesters
US8470359B2 (en)2000-11-132013-06-25Qlt Usa, Inc.Sustained release polymer
US7776310B2 (en)2000-11-162010-08-17Microspherix LlcFlexible and/or elastic brachytherapy seed or strand
EP2351840A1 (en)2000-11-282011-08-03Amgen Inc.Polypeptides involved in immune response
US6989247B2 (en)2000-11-282006-01-24Celltech R & D, Inc.Compositions and methods for diagnosing or treating psoriasis
US6599627B2 (en)2000-12-132003-07-29Purdue Research FoundationMicroencapsulation of drugs by solvent exchange
JP2004521111A (en)*2001-01-252004-07-15ユーロ−セルティーク，エス．エイ． Local anesthetics and usage
US7087726B2 (en)2001-02-222006-08-08Genentech, Inc.Anti-interferon-α antibodies
GB0111628D0 (en)2001-05-112001-07-04Scancell LtdBinding member
CA2449008A1 (en)2001-06-012002-12-12WyethCompositions and methods for systemic administration of sequences encoding bone morphogenetic proteins
AUPR546801A0 (en)2001-06-052001-06-28Commonwealth Scientific And Industrial Research OrganisationRecombinant antibodies
TWI267378B (en)2001-06-082006-12-01Wyeth CorpCalcium phosphate delivery vehicles for osteoinductive proteins
JP2004535431A (en)2001-06-222004-11-25サザン バイオシステムズ， インコーポレイテッド Zero-order long-term release coaxial implant
DE60235989D1 (en)2001-06-262010-05-27Amgen Fremont Inc ANTIBODIES AGAINST OPGL
TWI332407B (en)2001-06-292010-11-01Takeda Chemical Industries LtdControlled release composition and method of producting the same
EP2382982A3 (en)2001-08-242012-02-22Neuren Pharmaceuticals LimitedNeural regeneration peptide and methods for their use in treatment of brain damage
BR0212070A (en)2001-08-292004-09-28Genentech Inc bv8 nucleic acids and polypeptides with mitogenic activity
WO2003018782A2 (en)*2001-08-302003-03-06Stem Cell Therapeutics Inc.Differentiation of neural stem cells and therapeutic use theeof
GB0122113D0 (en)*2001-09-112001-10-31Astrazeneca AbComposition
EP1430114B1 (en)*2001-09-142012-01-18Stem Cell Therapeutics Inc.Prolactin induced increase in neural stem cell numbers and therapeutical use thereof
WO2003024471A2 (en)*2001-09-182003-03-27Stem Cell Therapeutics Inc.Effect of growth hormone and igf-1 on neural stem cells and therapeutic application
ATE419863T1 (en)2001-09-242009-01-15Imp Innovations Ltd PYY3-36 FOR REDUCING OR PREVENTING OBESITY
US20040186051A1 (en)2001-10-022004-09-23Kelley Robert FApo-2 ligand variants and uses thereof
AR045702A1 (en)2001-10-032005-11-09Chiron Corp COMPOSITIONS OF ASSISTANTS.
US7521053B2 (en)2001-10-112009-04-21Amgen Inc.Angiopoietin-2 specific binding agents
US7138370B2 (en)2001-10-112006-11-21Amgen Inc.Specific binding agents of human angiopoietin-2
ES2321701T3 (en)2001-10-122009-06-10Schering Corporation USE OF BISPECIFIC ANTIBODIES THAT JOIN THE FCEPSILONRI ACTIVATION RECEIVER AND THE OX2RA INHIBITION RECEIVER (CD200RA) TO REGULATE IMMUNE ANSWERS.
EP2322165A1 (en)2001-11-132011-05-18Genentech, Inc.Apo2 ligand/TRAIL formulations
NZ533434A (en)*2001-11-142006-11-30Alza CorpThixotropic gel composition for injectable deposition
CU23043A1 (en)2001-12-202005-05-20Ct Ingenieria Genetica Biotech PHARMACEUTICAL COMPOSITION CONTAINING EPIDROMIC GROWTH FACTOR (EGF) FOR THE PREVENTION OF AMBASSATION OF DIABETIC FOOT.
ES2425738T3 (en)2001-12-212013-10-17Human Genome Sciences, Inc. Albumin Fusion Proteins
US8058233B2 (en)2002-01-102011-11-15Oregon Health And Science UniversityModification of feeding behavior using PYY and GLP-1
AU2003201998C1 (en)2002-01-102012-10-25Imperial Innovations LimitedModification of feeding behavior
US7662924B2 (en)2002-02-222010-02-16The Board Of Trustees Of The University Of IllinoisBeta chain-associated regulator of apoptosis
WO2003079990A2 (en)*2002-03-192003-10-02Purdue Research FoundationMicroencapsulation using ultrasonic atomizers
JP4761710B2 (en)2002-04-052011-08-31アムジェン インコーポレイテッド Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
EP1500665B1 (en)2002-04-152011-06-15Chugai Seiyaku Kabushiki KaishaMETHODS FOR CONSTRUCTING scDb LIBRARIES
AU2003235833A1 (en)2002-04-262003-11-10Chugai Seiyaku Kabushiki KaishaMethod of screening agonistic antibody
US8623393B2 (en)2002-04-292014-01-07Gel-Del Technologies, Inc.Biomatrix structural containment and fixation systems and methods of use thereof
AU2002304965A1 (en)2002-05-242003-12-12Zensun (Shanghai) Sci-Tech.LtdNeuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
EP2305710A3 (en)2002-06-032013-05-29Genentech, Inc.Synthetic antibody phage libraries
DE10227232A1 (en)*2002-06-182004-01-15Aventis Pharma Deutschland Gmbh Sour insulin preparations with improved stability
AU2003247609A1 (en)2002-06-242004-01-06Genentech, Inc.Apo-2 ligand/trail variants and uses thereof
US20040001889A1 (en)2002-06-252004-01-01Guohua ChenShort duration depot formulations
US20050232995A1 (en)2002-07-292005-10-20Yam Nyomi VMethods and dosage forms for controlled delivery of paliperidone and risperidone
WO2004011497A1 (en)*2002-07-312004-02-05Stem Cell Therapeutics Inc.Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap)
US20040142393A1 (en)*2002-08-012004-07-22Cooper Garth James SmithMethods of use of compounds with preptin function
US8075585B2 (en)*2002-08-292011-12-13Stryker CorporationDevice and method for treatment of a vascular defect
BRPI0314038B8 (en)2002-09-062021-05-25Amgen Inc isolated human antibody, isolated nucleic acid molecule, vector, use of an antibody, and pharmaceutical composition
AU2003285874A1 (en)2002-10-162004-05-04Amgen Inc.HUMAN ANTI-IFN-Gamma NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-Gamma PATHWAY INHIBITORS
US20040086532A1 (en)*2002-11-052004-05-06Allergan, Inc.,Botulinum toxin formulations for oral administration
CA2506129C (en)2002-11-152015-02-17Idenix (Cayman) Limited2'-branched nucleosides and flaviviridae mutation
ATE472556T1 (en)2002-12-022010-07-15Amgen Fremont Inc ANTIBODIES DIRECTED AGAINST THE TUMOR NECROSIS FACTOR AND THEIR USES
SI1575569T1 (en)2002-12-132010-12-31Durect CorpOral drug delivery system comprising high viscosity liquid carrier materials
US7022481B2 (en)2002-12-192006-04-04Rosetta Inpharmatics LlcMethods of using glucan synthase pathway reporter genes to screen for antifungal compounds
JP2006517191A (en)2002-12-302006-07-20アムジエン・インコーポレーテツド Combination therapy using costimulatory factors
GB0300571D0 (en)2003-01-102003-02-12Imp College Innovations LtdModification of feeding behaviour
EP1440992A1 (en)*2003-01-212004-07-28Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.)Catalyst composition for (co)polymerisation of lactide and glycolide
US7772188B2 (en)2003-01-282010-08-10Ironwood Pharmaceuticals, Inc.Methods and compositions for the treatment of gastrointestinal disorders
CN100589839C (en)2003-01-282010-02-17艾恩伍德医药品股份有限公司Polypeptide and pharmaceutical composition containing the same
GB0304726D0 (en)*2003-03-012003-04-02Ardana Bioscience LtdNew Process
CA3007908A1 (en)2003-03-072005-04-14Dsm Ip Assets B.V.Hydrolases, nucleic acids encoding them and methods for making and using them
CA2515288A1 (en)2003-03-122004-09-23Genentech, Inc.Compositions with hematopoietic and immune activity
WO2004082796A2 (en)2003-03-142004-09-30The Trustees Of Columbia University In The City Ofnew YorkSystems and methods of blood-based therapies having a microfluidic membraneless exchange device
US20060076295A1 (en)*2004-03-152006-04-13The Trustees Of Columbia University In The City Of New YorkSystems and methods of blood-based therapies having a microfluidic membraneless exchange device
DK1613750T3 (en)2003-03-192016-01-18Amgen Fremont IncANTIBODIES TO T CELL AND MUCINDO immunoglobulin-binding domain 1 (TIM-1) antigen and uses thereof
SI2248899T1 (en)2003-03-192015-07-31Biogen Ma Inc.NOGO receptor binding protein
US20070264285A1 (en)*2003-04-252007-11-15O'hagan DerekCompositions Comprising Cationic Microparticles And Hcv B1e2 Dna And Methods Of Use Thereof
ES2383752T3 (en)2003-05-152012-06-26Trustees Of Tufts College GLP-1 stable analogs
WO2004103313A2 (en)2003-05-202004-12-02The American National Red CrossMethods of reducing vascular permeability in tissue by inhibition of tissue plasminogen activator (tpa) and tpa inhibitors useful therein
CN104119439A (en)2003-06-272014-10-29艾默根佛蒙特有限公司Antibodies directed to deletion mutants of epidermal growth factor receptor and uses thereof
DK1648998T3 (en)2003-07-182015-01-05Amgen Inc Specific binding agents for hepatocyte growth factor
US8343513B2 (en)2003-07-182013-01-01Oakwood Laboratories, LlcPrevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions
US8541051B2 (en)*2003-08-142013-09-24Halliburton Energy Services, Inc.On-the fly coating of acid-releasing degradable material onto a particulate
WO2005020933A2 (en)*2003-09-022005-03-10University Of South FloridaNanoparticles for drug-delivery
GB0320806D0 (en)2003-09-052003-10-08Astrazeneca AbTherapeutic treatment
HUE027218T2 (en)2003-09-122016-10-28Ipsen Biopharmaceuticals IncMethods for treatment of insulin-like growth factor-I(IGF-I) deficiency
PL1675608T3 (en)2003-09-122007-11-30Wyeth CorpInjectable calcium phosphate solid rods for delivery of osteogenic proteins
US7309232B2 (en)*2003-10-102007-12-18Dentigenix Inc.Methods for treating dental conditions using tissue scaffolds
US20050080313A1 (en)*2003-10-102005-04-14Stewart Daren L.Applicator for radiation treatment of a cavity
US7783006B2 (en)*2003-10-102010-08-24Xoft, Inc.Radiation treatment using x-ray source
AU2003271174A1 (en)2003-10-102005-04-27Chugai Seiyaku Kabushiki KaishaDouble specific antibodies substituting for functional protein
JPWO2005035754A1 (en)2003-10-142006-12-21中外製薬株式会社 Bispecific antibodies that replace functional proteins
CA2543484C (en)2003-10-272014-02-04Amgen Inc.Modulation of immune response to an immunogen with ctla-4 and tnfbp
DK1682537T3 (en)2003-11-052012-07-09Sarcode Bioscience Inc Cell adhesion modulators
WO2005067889A1 (en)*2003-12-302005-07-28Durect CorporationPolymeric implants, preferably containing a mixture of peg and plg, for controlled release of active agents, preferably a gnrh
CN100534527C (en)*2003-12-302009-09-02杜雷科特公司Polymeric implants, preferably containing a mixture of PEG and PLG, for controlled release of active agents, preferably a GnRH
KR20070006708A (en)*2004-01-072007-01-11트라이머리스 인코퍼레이티드 HIV Ig 41 HR2-derived synthetic peptides and their use in the treatment of inhibiting the transmission of human immunodeficiency virus
AU2005211385B2 (en)2004-02-022008-12-11Ambrx, Inc.Modified human growth hormone polypeptides and their uses
US20070066525A1 (en)*2004-02-042007-03-22Lee John CCompositions and therapeutic methods using morphogenic proteins
AU2005211847B2 (en)2004-02-132011-02-24Stem Cell Therapeutics Corp.Use of luteinizing hormone (LH) and chorionic gonadotropin (hCG) for proliferation of neural stem cells and neurogenesis
WO2005090564A1 (en)2004-03-192005-09-29Genomidea Inc.Gene promoting vascular endothelial cell growth
US20050260679A1 (en)2004-03-192005-11-24Sirid-Aimee KellermanReducing the risk of human anti-human antibodies through V gene manipulation
KR20060132006A (en)2004-03-232006-12-20비오겐 아이덱 엠에이 아이엔씨. Receptor Coupling Agents and Their Therapeutic Uses
GB0410627D0 (en)2004-05-122004-06-16Scancell LtdSpecific binding members
EP1598428A1 (en)2004-05-182005-11-23Georg DewaldMethods and kits to detect Hereditary angioedema type III
CA2567813C (en)2004-05-232015-11-24Gerard M. HouseyTheramutein modulators
JP5201987B2 (en)2004-05-252013-06-05ストライカー コーポレイション Use of morphogenic proteins to treat cartilage defects
BRPI0512235A (en)2004-06-182008-02-19Ambrx Inc antigen-binding polypeptides and their uses
ATE501252T1 (en)2004-06-222011-03-15Univ Illinois METHOD FOR INHIBITING TUMOR CELL GROWTH USING FOXM1 SIRNS
JP4960865B2 (en)2004-06-242012-06-27バイオジェン・アイデック・エムエイ・インコーポレイテッド Treatment of conditions related to demyelination
US20080280973A1 (en)*2004-06-282008-11-13Wender Paul ALaulimalide Analogues as Therapeutic Agents
US20060004185A1 (en)*2004-07-012006-01-05Leese Richard APeptide antibiotics and peptide intermediates for their prepartion
ME00226B (en)2004-07-152011-02-10Medarex LlcHuman anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
MX2007000728A (en)2004-07-212007-03-15Ambrx IncBiosynthetic polypeptides utilizing non-naturally encoded amino acids.
EP1789070B1 (en)2004-08-032012-10-24Biogen Idec MA Inc.Taj in neuronal function
ES2432556T3 (en)*2004-08-042013-12-04Evonik Corporation Methods for manufacturing supply devices and their devices
ES2414460T3 (en)2004-08-042013-07-19Amgen Inc. Antibodies for Dkk-1
DK1786400T3 (en)2004-08-122009-06-29Quest Pharmaceutical Services Pharmaceutical composition for controlled release delivery of biologically active compounds
JP5070052B2 (en)2004-08-172012-11-07ザ・ジョンズ・ホプキンス・ユニバーシティ PDE5 inhibitor composition and method for treating heart disease
EP1802326A2 (en)*2004-09-092007-07-04Stryker CorporationMethods for treating bone tumors using bone morphogenic proteins
LT2767292T (en)*2004-09-172016-12-12Durect CorporationSustained Local Anesthetic Composition Containing SAIB
CA2583061C (en)2004-10-062015-02-17Kwang Guan TayAntibody production method
FR2876379B1 (en)*2004-10-082008-09-05Isochem Sa PROCESS FOR POLYMERIZING O-CARBOXY ANHYDRIDES
WO2006041048A1 (en)2004-10-152006-04-20Mie UniversityLiver regeneration/repair controlling agent
ATE492563T1 (en)2004-11-172011-01-15Amgen Inc COMPLETE HUMAN MONOCLONAL ANTIBODIES AGAINST IL-13
US7619007B2 (en)*2004-11-232009-11-17Adamas Pharmaceuticals, Inc.Method and composition for administering an NMDA receptor antagonist to a subject
GB0425854D0 (en)*2004-11-252004-12-29Astrazeneca AbTherapeutic treatment
US7572444B2 (en)2004-12-202009-08-11Amgen Fremont Inc.Binding proteins specific for human matriptase
KR101017301B1 (en)2004-12-212011-02-28메드임뮨 리미티드 Antibodies to Angiopoietin-2 and Uses thereof
EP1828224B1 (en)2004-12-222016-04-06Ambrx, Inc.Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
KR20070090023A (en)2004-12-222007-09-04암브룩스, 인코포레이티드Modified human growth hormone
CN101163464A (en)*2004-12-232008-04-16杜雷科特公司Polymeric implants, preferably containing a mixture of PEG and PLG, for controlled release of a GnRH
EP2351576A1 (en)*2004-12-292011-08-03Mannkind CorporationMethods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
EP1851245B1 (en)2005-01-262012-10-10Amgen Fremont Inc.Antibodies against interleukin-1 beta
EP1874282B1 (en)2005-04-062010-09-15Adamas Pharmaceuticals, Inc.Methods and compositions for treatment of cns disorders
DK2824183T3 (en)2005-04-082020-09-28Chugai Pharmaceutical Co Ltd Process for the production of bispecific antibodies
EP1871796A4 (en)*2005-04-202009-01-14Auckland Uniservices LtdVesiculins
MX2007013213A (en)*2005-04-252007-12-12Amgen IncBiodegradable peptide sustained release compositions containing porogens.
EP1716847B1 (en)2005-04-282008-01-02Nipro CorporationBioabsorbable pharmaceutical formulation comprising a PLGA copolymer
WO2006124699A2 (en)2005-05-122006-11-23Wisconsin Alumni Research FoundationBlockade of pin1 prevents cytokine production by activated immune cells
CA2960117C (en)*2005-05-172018-01-30Sarcode Bioscience Inc.Lfa-1 antagonists for the treatment of eye disorders
US8431110B2 (en)2005-05-232013-04-30Hmi Medical Innovations, Llc.Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
TW200718780A (en)2005-06-102007-05-16Chugai Pharmaceutical Co LtdSc(Fv)2 site-directed mutant
CN101237890A (en)2005-06-102008-08-06中外制药株式会社Stabilizer for protein preparation comprising meglumine and use thereof
US20080311078A1 (en)2005-06-142008-12-18Gokarn Yatin RSelf-Buffering Protein Formulations
KR101502920B1 (en)2005-06-212015-03-17조마 (유에스) 엘엘씨IL-1β Binding antibodies and fragments thereof
CA2614421A1 (en)2005-07-082007-01-18Biogen Idec Ma Inc.Sp35 antibodies and uses thereof
CA2614972C (en)2005-07-182014-08-19Amgen Inc.Human anti-b7rp1 neutralizing antibodies
US20070027105A1 (en)2005-07-262007-02-01Alza CorporationPeroxide removal from drug delivery vehicle
CA2616537A1 (en)2005-07-272007-02-01University Of Florida Research Foundation, Inc.Small compounds that correct protein misfolding and uses thereof
BRPI0615573A2 (en)2005-09-082011-05-24Tufts College stabilized glp-1 analogs
WO2007036033A1 (en)2005-09-272007-04-05Stem Cell Therapeutics Corp.Oligodendrocyte precursor cell proliferation regulated by prolactin
US7932231B2 (en)2005-09-292011-04-26Ipsen Pharma, S.A.S.Compositions and methods for stimulating gastrointestinal motility
US8852638B2 (en)2005-09-302014-10-07Durect CorporationSustained release small molecule drug formulation
EP3037544A1 (en)2005-10-132016-06-29Human Genome Sciences, Inc.Methods and compositions for use in treatment of systemic lupus erythematosus (sle) patients with autoantibody positive diseases
BRPI0617378B8 (en)2005-10-142022-09-20Chugai Pharmaceutical Co Ltd USE OF AN IL-6 INHIBITOR TO PRODUCE A PHARMACEUTICAL COMPOSITION TO SUPPRESS DAMAGE TO AN ISLE TRANSPLANTATION AFTER ISLE TRANSPLANTATION; AND IMPROVE THE FEASIBILITY OF AN ISLAND IN AN ISLAND TRANSPLANTATION
BRPI0617664B8 (en)2005-10-212021-05-25Chugai Pharmaceutical Co Ltd use of an antibody recognizing IL-6 for the production of a pharmaceutical composition to treat myocardial infarction or suppress left ventricular remodeling after myocardial infarction
KR20080080109A (en)2005-11-042008-09-02바이오겐 아이덱 엠에이 인코포레이티드 Methods of promoting neurite outgrowth and survival of dopaminergic neurons
US8882747B2 (en)*2005-11-092014-11-11The Invention Science Fund I, LlcSubstance delivery system
JP2009515897A (en)2005-11-102009-04-16キュラジェン コーポレイション Methods of treating ovarian and renal cancer using antibodies to immunoglobulin domains of murine domain and mucin domain 1 (TIM-1) antigen
EP2338517A1 (en)2005-11-142011-06-29Ribomic IncMethod for treatment or prevention of disease associated with functional disorder of regulatory T cell
TW200736277A (en)2005-11-142007-10-01Amgen IncRANKL antibody-PTH/PTHrP chimeric molecules
AR057582A1 (en)2005-11-152007-12-05Nat Hospital Organization AGENTS TO DELETE INDUCTION OF CYTOTOXIC T LYMPHOCYTES
US20090018029A1 (en)2005-11-162009-01-15Ambrx, Inc.Methods and Compositions Comprising Non-Natural Amino Acids
WO2007061029A1 (en)2005-11-252007-05-31Keio UniversityTherapeutic agent for prostate cancer
AU2006321287B2 (en)2005-12-012013-05-09The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near DublinCompositions and methods relating to treatment of cancer and infectious diseases
AU2006320479B2 (en)2005-12-022012-11-08Biogen Ma Inc.Treatment of conditions involving demyelination
US20070213264A1 (en)2005-12-022007-09-13Mingdong ZhouNeuregulin variants and methods of screening and using thereof
EP1962872B1 (en)2005-12-052014-05-28The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near DublinCompositions and methods for modulating an immune response
WO2008024128A2 (en)2005-12-052008-02-28Simon DelagraveLoop-variant pdz domains as biotherapeutics, diagnostics and research reagents
RU2492185C2 (en)2005-12-132013-09-10Астразенека АбBinding proteins, specific with respect to insulin-like growth factors, and their application
DK1969003T3 (en)2005-12-142010-12-13Hermo Pharma Ltd Applications of a neurotrophic factor protein
AU2006324477A1 (en)2005-12-152007-06-21Medimmune LimitedCombination of angiopoietin-2 antagonist and of VEGF-A, KDR and/or Flt1 antagonist for treating cancer
US20070154546A1 (en)*2005-12-302007-07-05Zhang Jack YSustained release pharmaceutical compositions
US20070190127A1 (en)2005-12-302007-08-16Mingdong ZhouExtended release of neuregulin for improved cardiac function
US20100167341A1 (en)2006-01-172010-07-01Dnavec CorporationNovel protein expression system
AU2007207618B2 (en)2006-01-182011-03-24Foresee Pharmaceuticals Co., Ltd.Pharmaceutical compositions with enhanced stability
EP1981902B1 (en)2006-01-272015-07-29Biogen MA Inc.Nogo receptor antagonists
JP5033643B2 (en)2006-01-272012-09-26学校法人慶應義塾 Therapeutic agent for diseases associated with choroidal neovascularization
CU23388B6 (en)*2006-01-312009-07-16Ct Ingenieria Genetica Biotech PHARMACEUTICAL COMPOSITION OF MICROSPHERES TO PREVENT AMPUTATION OF THE DIABETIC FOOT
US7756524B1 (en)2006-01-312010-07-13Nextel Communications Inc.System and method for partially count-based allocation of vocoder resources
US20070178138A1 (en)*2006-02-012007-08-02Allergan, Inc.Biodegradable non-opthalmic implants and related methods
PT1989220E (en)*2006-02-022012-03-23Trimeris IncHiv fusion inhibitor peptides with improved biological properties
EP2216403A3 (en)2006-02-022010-11-24Verenium CorporationEsterases and related nucleic acids and methods
US8143220B2 (en)*2006-03-172012-03-27Stem Cell Therapeutics Corp.Dosing regimens for neural stem cell proliferating agents and differentiating agents for the treatment of neurological disorders
EP1837014A1 (en)*2006-03-212007-09-26Hexal AgSubcutaneous implants containing a degradation-resistant polylactide polymer and a LH-RH analogue
JP5754875B2 (en)2006-04-072015-07-29国立大学法人大阪大学 Muscle regeneration promoter
TW200813091A (en)2006-04-102008-03-16Amgen Fremont IncTargeted binding agents directed to uPAR and uses thereof
EP2548579B1 (en)2006-05-172015-09-02The Ludwig Institute for Cancer ResearchTargeting VEGF-B regulation of fatty acid transporters to modulate human diseases
US20090298761A1 (en)2006-05-172009-12-03Donald EngelmanMethods of treating cartilage defects using a soluble morphogenic protein complex
US7403325B2 (en)*2006-05-192008-07-22Xerox CorporationElectrophoretic display device
JP2010506599A (en)*2006-05-222010-03-04ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク A method for exchanging components between a first fluid and a second fluid, a method for cleaning a first component from a first fluid, a blood processing method, a fluid treatment device, a first fluid and first and second components Apparatus for exchanging components with second fluid, apparatus for exchanging components between first fluid and second fluid, and method for separating blood cells from plasma
WO2007139589A1 (en)2006-05-262007-12-06Bristol-Myers Squibb CompanySustained release glp-1 receptor modulators
WO2007143121A2 (en)2006-06-012007-12-13President And Fellows Of Harvard CollegePurification of a bivalently active antibody using a non-chromatographic method
DK2047863T3 (en)2006-06-082013-09-16Chugai Pharmaceutical Co Ltd MEDICINE FOR PREVENTION OR TREATMENT OF INFLAMMATORY DISEASES
GB0611405D0 (en)2006-06-092006-07-19Univ BelfastFKBP-L: A novel inhibitor of angiogenesis
CA2657385A1 (en)2006-07-132008-01-17Naoki KimuraCell death inducer
US20080015546A1 (en)*2006-07-132008-01-17Casas Jesus WMethods and formulations for optimal local delivery of cell therapy via minimally invasive procedures
WO2008010556A1 (en)2006-07-212008-01-24Chugai Seiyaku Kabushiki KaishaRemedy for renal disease
US20100105610A1 (en)2006-07-282010-04-29Children's Memorial HospitalMethods of Inhibiting Tumor Cell Aggressiveness Using the Microenvironment of Human Embryonic Stem Cells
CL2007002225A1 (en)2006-08-032008-04-18Astrazeneca Ab SPECIFIC UNION AGENT FOR A RECEIVER OF THE GROWTH FACTOR DERIVED FROM PLATES (PDGFR-ALFA); NUCLEIC ACID MOLECULA THAT CODIFIES IT; VECTOR AND CELL GUESTS THAT UNDERSTAND IT; CONJUGADO UNDERSTANDING THE AGENT; AND USE OF THE AGENT OF A
WO2008019368A2 (en)2006-08-072008-02-14Teva Biopharmaceuticals Usa, Inc.Albumin-insulin fusion proteins
CA2663083A1 (en)2006-09-082008-03-13Ambrx, Inc.Modified human plasma polypeptide or fc scaffolds and their uses
US7833527B2 (en)2006-10-022010-11-16Amgen Inc.Methods of treating psoriasis using IL-17 Receptor A antibodies
EP2311481A3 (en)2006-10-202013-10-16Biogen Idec MA Inc.Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
US8338376B2 (en)2006-10-202012-12-25Biogen Idec Ma Inc.Compositions comprising variant LT-B-R-IG fusion proteins
PT2117521E (en)2006-11-032012-09-10Durect CorpTransdermal delivery systems comprising bupivacaine
WO2008061019A2 (en)2006-11-142008-05-22Genentech, Inc.Modulators of neuronal regeneration
US7935796B2 (en)2006-12-082011-05-03Lexicon Pharmaceuticals, Inc.Monoclonal antibodies against ANGPTL3
TWI428346B (en)2006-12-132014-03-01Imp Innovations LtdNovel compounds and their effects on feeding behaviour
JP4564098B2 (en)2006-12-182010-10-20武田薬品工業株式会社 Sustained release composition and method for producing the same
RU2554747C9 (en)2006-12-202015-10-20Ксома (Сша) ЛлсMethod of treating il-1beta-dependent diseases
NZ577976A (en)2007-01-092011-12-22Biogen Idec IncSp35 antibodies and uses thereof
US8128926B2 (en)2007-01-092012-03-06Biogen Idec Ma Inc.Sp35 antibodies and uses thereof
AU2008208321B2 (en)2007-01-232013-03-21Chugai Seiyaku Kabushiki KaishaChronic rejection inhibitor
GEP20135853B (en)2007-02-022013-06-25Univ Pierre And Marie CurieMethod of myelination and oligodendrocyte differentiation promotion
US8501678B2 (en)2007-03-062013-08-06Atara Biotherapeutics, Inc.Variant activin receptor polypeptides and uses thereof
US9610327B2 (en)2007-03-062017-04-04Amgen Inc.Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
TWI573802B (en)2007-03-062017-03-11安美基公司 Mutant activin receptor polypeptide and use thereof
CL2008000719A1 (en)2007-03-122008-09-05Univ Tokushima Chugai Seiyaku THERAPEUTIC AGENT FOR CANCER RESISTANT TO CHEMOTHERAPEUTIC AGENTS THAT UNDERSTAND AN ANTIBODY THAT RECOGNIZES IT CLASS I AS ACTIVE INGREDIENT; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH ANTIBODY; AND METHOD TO TREAT CANCER RESISTANT TO
ES2385114T3 (en)2007-03-302012-07-18Ambrx, Inc. Modified FGF-21 polypeptides and their uses
CA2682848A1 (en)*2007-04-032008-10-16Trimeris, Inc.Novel formulations for delivery of antiviral peptide therapeutics
US20100290982A1 (en)*2007-04-132010-11-18University Of North Texas Health Science Center At Fort WorthSolid in oil/water emulsion-diffusion-evaporation formulation for preparing curcumin-loaded plga nanoparticles
CA2683777C (en)2007-04-132016-08-23University Of North Texas Health Science Center At Fort WorthFormulation of active agent loaded activated plga nanoparticles for targeted cancer nano-therapeutics
JP5443979B2 (en)2007-05-112014-03-19備前化成株式会社 Novel leukotriene receptor antagonist
DK2167039T3 (en)2007-05-182017-01-09Durect CorpImproved depot formulations
MX354603B (en)2007-05-252018-03-13Indivior Uk LtdSustained delivery formulations of risperidone compounds.
US8969514B2 (en)2007-06-042015-03-03Synergy Pharmaceuticals, Inc.Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US20100120694A1 (en)2008-06-042010-05-13Synergy Pharmaceuticals, Inc.Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
CA2688161C (en)2007-06-042020-10-20Kunwar ShailubhaiAgonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
GB0710976D0 (en)2007-06-072007-07-18BioalvoAm Screening method
EA020456B1 (en)2007-06-142014-11-28Байоджен Айдек Ма Инк.Pharmaceutical composition comprising vla-4 binding antibody for subcutaneous or intramuscular administration
WO2009002931A2 (en)2007-06-222008-12-31Children's Medical Center CorporationMethods and uses thereof of prosaposin
CA2691166A1 (en)2007-06-272008-12-31Liu DongxuPolypeptides and polynucleotides for artemin and related ligands, and methods of use thereof
US20100129355A1 (en)2007-07-262010-05-27Osaka UniversityTherapeutic agents for ocular inflammatory disease comprising interleukin 6 receptor inhibitor as active ingredient
DE102007036101A1 (en)2007-08-012009-02-05Boehringer Ingelheim Pharma Gmbh & Co. Kg New glycolide-rich copolymers
TW200916113A (en)2007-08-082009-04-16Sod Conseils Rech ApplicMethod for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue
NZ583282A (en)2007-08-212012-09-28Amgen IncHuman c-fms antigen binding proteins
JOP20080381B1 (en)2007-08-232023-03-28Amgen IncAntigen Binding Proteins to Proprotein Convertase subtillisin Kexin type 9 (pcsk9)
EP2615113A3 (en)2007-08-232013-11-13Amgen Inc.Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US7982016B2 (en)2007-09-102011-07-19Amgen Inc.Antigen binding proteins capable of binding thymic stromal lymphopoietin
US20090156488A1 (en)2007-09-122009-06-18Zensun (Shanghai) Science & Technology LimitedUse of neuregulin for organ preservation
TW200918553A (en)2007-09-182009-05-01Amgen IncHuman GM-CSF antigen binding proteins
EP2040075A1 (en)2007-09-242009-03-25Julius-Maximilians-Universität WürzburgCompounds and markers for surface-enhanced raman scattering
MX2010003179A (en)*2007-09-252010-04-30Trimeris IncMethods of synthesis for therapeuthic anti-hiv peptides.
NZ584726A (en)2007-09-262012-09-28U3 Pharma GmbhHeparin-binding epidermal growth factor-like growth factor antigen binding proteins
JP5264752B2 (en)2007-10-022013-08-14中外製薬株式会社 Graft-versus-host disease therapeutic agent comprising an interleukin 6 receptor inhibitor as an active ingredient
CN101998855A (en)*2007-10-022011-03-30戴维·布兰斯基 Endocannabinoids for Enhanced Growth and Development in Babies
US20090123508A1 (en)*2007-10-042009-05-14Boston Scientific Scimed, Inc.Implantable Drug Depot for Intrathecal Drug Delivery System for Pain Management
EP3167886B1 (en)2007-10-192020-08-05Novartis AGCompositions and methods for treatment of macular edema
EP2219620B1 (en)*2007-11-132017-07-19Surmodics, Inc.Viscous terpolymers as drug delivery platform
ME01026B (en)2007-11-162012-10-20Univ RockefellerAntibodies specific for the protofibril form of beta-amyloid protein
ES2632504T3 (en)2007-11-202017-09-13Ambrx, Inc. Modified insulin polypeptides and their uses
JP5682995B2 (en)2007-12-052015-03-11中外製薬株式会社 Anti-NR10 antibody and use thereof
KR101595134B1 (en)2007-12-052016-02-17추가이 세이야쿠 가부시키가이샤Therapeutic agent for pruritus
US8415401B2 (en)2007-12-062013-04-09Durect CorporationOral pharmaceutical dosage forms
US20110262425A1 (en)2007-12-122011-10-27National Cancer CenterTherapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
WO2009086003A1 (en)2007-12-202009-07-09Xoma Technology Ltd.Methods for the treatment of gout
US20090181068A1 (en)*2008-01-142009-07-16Dunn Richard LLow Viscosity Liquid Polymeric Delivery System
BRPI0907473A2 (en)*2008-02-042019-09-24Univ Columbia fluid separation methods, systems and devices
US9938333B2 (en)2008-02-082018-04-10Ambrx, Inc.Modified leptin polypeptides and their uses
JO2913B1 (en)2008-02-202015-09-15امجين إنك,Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
ES2635515T3 (en)*2008-02-222017-10-04Toray Industries, Inc. Microparticle and pharmaceutical composition thereof
US8080562B2 (en)2008-04-152011-12-20Sarcode Bioscience Inc.Crystalline pharmaceutical and methods of preparation and use thereof
FI20080326A0 (en)2008-04-302008-04-30Licentia Oy Neurotrophic factor MANF and its uses
JOP20190083A1 (en)2008-06-042017-06-16Amgen IncFgf21 mutant fusion polypeptides and uses thereof
CN104906581A (en)2008-06-052015-09-16国立研究开发法人国立癌症研究中心Neuroinvasion inhibitor
AU2009266098B2 (en)2008-06-092015-01-22Ludwig-Maximilians-Universitat MunchenNew drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
EP2671891A3 (en)2008-06-272014-03-05Amgen Inc.Ang-2 inhibition to treat multiple sclerosis
US8058406B2 (en)2008-07-092011-11-15Biogen Idec Ma Inc.Composition comprising antibodies to LINGO or fragments thereof
ES2624828T3 (en)2008-07-162017-07-17Synergy Pharmaceuticals Inc. Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and others
EP2318029B1 (en)2008-07-232017-11-01Ambrx, Inc.Modified bovine g-csf polypeptides and their uses
EP2907531A1 (en)2008-07-302015-08-19Mesynthes LimitedMethod of separating or decellularising layers of tissue
US8153391B2 (en)2008-08-292012-04-10Bunge Oils, Inc.Hydrolases, nucleic acids encoding them and methods for making and using them
US8357503B2 (en)2008-08-292013-01-22Bunge Oils, Inc.Hydrolases, nucleic acids encoding them and methods for making and using them
US8198062B2 (en)2008-08-292012-06-12Dsm Ip Assets B.V.Hydrolases, nucleic acids encoding them and methods for making and using them
JP5859307B2 (en)2008-09-102016-02-10ジェネンテック， インコーポレイテッド Methods for inhibiting ocular neovascularization
RU2581962C2 (en)2008-09-192016-04-20Медиммун ЛлкTargeted binding agents against dll4 and application thereof
MX357314B (en)2008-09-262018-07-04Ambrx IncNon-natural amino acid replication-dependent microorganisms and vaccines.
NZ592250A (en)2008-09-262012-11-30Lilly Co EliModified animal erythropoietin polypeptides and their uses
CA2739615C (en)2008-10-102017-12-05Amgen Inc.Fgf21 mutants comprising polyethylene glycol and uses thereof
EP2379585A2 (en)2008-10-102011-10-26Anaphore, Inc.Polypeptides that bind trail-ri and trail-r2
AU2009308293B2 (en)2008-10-222015-02-05Genentech, Inc.Modulation of axon degeneration
MX345226B (en)2008-10-292017-01-20Ablynx NvFormulations of single domain antigen binding molecules.
US20100260844A1 (en)2008-11-032010-10-14Scicinski Jan JOral pharmaceutical dosage forms
EP2362782A1 (en)2008-11-172011-09-07The Provost, Fellows, Foundation Scholars, and the other Members of Board, of the College of the Holy and Undivided Trinity of Queen ElizabethA vaccinia virus protein a46 peptide and use thereof
KR20170105124A (en)2008-11-262017-09-18암젠 인크Variants of activin iib receptor polypeptides and uses thereof
WO2010070136A2 (en)2008-12-192010-06-24Centre de Recherche Public de la SantéNovel caviidae allergens and uses thereof
WO2010072684A1 (en)2008-12-222010-07-01Universität RegensburgNorrin in the treatment of diseases associated with an increased tgf-beta activity
JO3382B1 (en)2008-12-232019-03-13Amgen IncHuman cgrp receptor binding antibodies
US8343912B2 (en)2008-12-232013-01-01Biosource Pharm, Inc.Antibiotic compositions for the treatment of gram negative infections
JP2012513194A (en)2008-12-232012-06-14アストラゼネカ アクチボラグ Targeted binding agents directed to α5β1 and uses thereof
US8951546B2 (en)2008-12-232015-02-10Surmodics Pharmaceuticals, Inc.Flexible implantable composites and implants comprising same
US8974808B2 (en)*2008-12-232015-03-10Surmodics, Inc.Elastic implantable composites and implants comprising same
US20100158978A1 (en)*2008-12-232010-06-24Peter MarklandBioactive spray coating compositions and methods of making and uses thereof
US20100168807A1 (en)*2008-12-232010-07-01Burton Kevin WBioactive terpolymer compositions and methods of making and using same
US9415197B2 (en)2008-12-232016-08-16Surmodics, Inc.Implantable suction cup composites and implants comprising same
KR101040396B1 (en)2009-01-202011-06-09한올바이오파마주식회사 Modified human thrombopoietin polypeptide fragment and method for preparing the same
US20100189763A1 (en)*2009-01-232010-07-29Heather NettlesControlled release systems from polymer blends
WO2010085608A1 (en)*2009-01-232010-07-29Surmodics Pharmaceuticals, Inc.Polymer mixtures comprising polymers having different non-repeating units and methods for making and using same
EP2396035A4 (en)2009-02-122012-09-12Human Genome Sciences Inc USE OF ANTAGONISTS OF THE B-LYMPHOCYTE STIMULATOR PROTEIN TO PROMOTE TRANSPLANT TOLERANCE
MX2011008542A (en)2009-02-132011-09-01Novartis AgNucleic acid molecule of a biosynthetic cluster encoding non ribosomal peptide synthases and uses thereof.
TW201031436A (en)*2009-02-162010-09-01Univ Nat TaiwanPharmaceutical composition for inhalation delivery and fabrication method thereof
CA2759667A1 (en)2009-02-182010-08-26Bayer Pharma AktiengesellschaftParticles comprising drospirenone encapsulated in a polymer
JP2010210772A (en)2009-03-132010-09-24Dainippon Screen Mfg Co LtdMethod of manufacturing liquid crystal display device
US20120052069A1 (en)2009-05-052012-03-01Amgen IncFgf21 mutants and uses thereof
CN102655877B (en)2009-05-052017-04-05安姆根有限公司 FGF21 mutants and uses thereof
EP2260857A1 (en)2009-06-112010-12-15Alfact InnovationNovel applications of HIP/PAP or derivatives thereof
WO2010144797A2 (en)2009-06-122010-12-16Vaccine Technologies, IncorporatedInfluenza vaccines with enhanced immunogenicity and uses thereof
IN2012DN00352A (en)2009-06-162015-08-21Bikam Pharmaceuticals Inc
WO2010148142A1 (en)2009-06-172010-12-23Amgen Inc.Chimeric fgf19 polypeptides and uses thereof
WO2011010131A1 (en)2009-07-212011-01-27Astrazeneca AbCompositions comprising an oxoisoquinoline methylbenzamide and a polymer
WO2011010132A1 (en)2009-07-212011-01-27Astrazeneca AbSustained-release composition comprising compound 600
US20120183539A1 (en)2009-07-312012-07-19Shin MaedaCancer Metastasis Inhibitor
TW201118166A (en)2009-09-242011-06-01Chugai Pharmaceutical Co LtdHLA class I-recognizing antibodies
EP2305285A1 (en)2009-09-292011-04-06Julius-Maximilians-Universität WürzburgMeans and methods for treating ischemic conditions
EP2305810A1 (en)2009-10-022011-04-06Technische Universität MünchenmiRNAs in the treatment of fibrosis
EP2308478A1 (en)2009-10-062011-04-13Abbott GmbH & Co. KGDelivery system for sustained release of a calcium-channel blocking agent
TW201117824A (en)2009-10-122011-06-01Amgen IncUse of IL-17 receptor a antigen binding proteins
US20120282266A1 (en)2009-10-162012-11-08Auckland Uniservices LimitedAnti-neoplastic uses of artemin antagonists
EP2492281B1 (en)2009-10-192018-04-11HanAll Biopharma Co., Ltd.Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof, and method for preparing same
WO2011050175A1 (en)2009-10-212011-04-28Sarcode CorporationCrystalline pharmaceutical and methods of preparation and use thereof
EP3011970A3 (en)2009-10-222016-06-08F. Hoffmann-La Roche AGModulation of axon degeneration
US8729058B2 (en)2009-10-272014-05-20Michael ZasloffMethods and compositions for treating and preventing viral infections
CN102770533B (en)2009-11-022016-11-23华盛顿大学 Therapeutic nuclease compositions and methods
WO2011060372A2 (en)2009-11-132011-05-19Puget Sound Blood CenterFactor viii b cell epitope variants having reduced immunogenicity
ES2646863T3 (en)2009-11-242017-12-18Medimmune Limited B7-H1 specific binding agents
WO2011066260A2 (en)2009-11-252011-06-03Michael ZasloffFormulations comprising aminosterols
US8491927B2 (en)2009-12-022013-07-23Nimble Epitech, LlcPharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
US8741343B2 (en)2009-12-022014-06-03Adamas Pharmaceuticals, Inc.Method of administering amantadine prior to a sleep period
UA109888C2 (en)2009-12-072015-10-26 ANTIBODY OR ANTIBODILITY ANTIBODY OR ITS BINDING TO THE β-CLOTE, FGF RECEPTORS AND THEIR COMPLEXES
CA2822026C (en)2009-12-172018-06-12Children's Medical Center CorporationSaposin-a derived peptides and uses thereof
US20120283171A1 (en)2009-12-212012-11-08Ambrx, Inc.Modified bovine somatotropin polypeptides and their uses
US20120283172A1 (en)2009-12-212012-11-08Ambrx, Inc.Modified porcine somatotropin polypeptides and their uses
US8936804B2 (en)2010-01-152015-01-20Rutgers, The State University Of New JerseyUse of vanadium compounds to accelerate bone healing
WO2011089161A1 (en)2010-01-192011-07-28Medizinische Universität WienPharmaceutical compositions comprising lignans and their derivatives for the medical management of angiogenesis and hypovascularity
EP2528938A4 (en)2010-01-272013-10-23Childrens Medical Center PROANGIOGENIC FRAGMENTS OF PROMININ 1 AND USES THEREOF
WO2011092242A1 (en)2010-01-282011-08-04Novo Nordisk Health Care AgFactor vii fusion polypeptides
WO2011099007A1 (en)2010-02-102011-08-18Nayacure Therapeutics Ltd.Pharmaceutical compositions and methods for the treatment and prevention of cancer
GB201003559D0 (en)2010-03-032010-04-21Proteo Biotech AgNovel use of elafin
WO2011112906A2 (en)2010-03-122011-09-15Children's Medical Center CorporationNovel immunogens and methods for discovery and screening thereof
CN103038255A (en)2010-03-262013-04-10国立大学法人德岛大学Novel anti-CD98 antibody and use thereof
JP2013523184A (en)2010-04-152013-06-17アムジエン・インコーポレーテツド Human FGF receptor and β-KLOTHO binding protein
EP2561068A1 (en)2010-04-192013-02-27Medizinische Universität InnsbruckTmem195 encodes for tetrahydrobiopterin-dependent alkylglycerol monooxygenase activity
KR101868165B1 (en)2010-04-222018-07-19인트라-셀룰라 써래피스, 인코퍼레이티드.Organic compounds
GB201007531D0 (en)2010-05-052010-06-23Imp Innovations LtdComposition
US9320756B2 (en)2010-05-072016-04-26Centre National De La Recherche ScientifiqueUCP1 (thermogenin)—inducing agents for use in the treatment of a disorder of the energy homeostasis
CA2800065A1 (en)2010-05-212011-11-24Peptimed, Inc.Reagents and methods for treating cancer
WO2011149046A1 (en)2010-05-282011-12-01独立行政法人国立がん研究センターTherapeutic agent for pancreatic cancer
PL2578231T3 (en)2010-05-282023-01-16Chugai Seiyaku Kabushiki KaishaAntitumor t cell response enhancer
CN114010776A (en)2010-06-092022-02-08疫苗技术股份有限公司Therapeutic immunization of HIV-infected persons for enhancing antiretroviral therapy
KR20200144591A (en)2010-06-162020-12-29앙도르쉐르슈 인코포레이티드Methods of treating or preventing estrogen-related diseases
EP2582720B1 (en)2010-06-182014-05-21XiberScience GmbHPeptides as active agents to stabilize biological barriers
US8415307B1 (en)2010-06-232013-04-09Biosource Pharm, Inc.Antibiotic compositions for the treatment of gram negative infections
US9364518B2 (en)2010-06-242016-06-14Torrent Pharmaceuticals LimitedPharmaceutical composition containing goserelin for in-situ implant
US9211175B2 (en)2010-07-082015-12-15Covidien LpSelf-detachable medical devices
FR2962646B1 (en)2010-07-162012-06-22Sofradim Production PROSTHETIC WITH RADIO OPAQUE ELEMENT
JP2013536175A (en)2010-07-162013-09-19アブリンクス エン．ヴェー． Modified single domain antigen binding molecules and uses thereof
UY33517A (en)2010-07-192012-02-29Astrazeneca Ab Pharmaceutical depot for 5-fluoro-2 - [[(1S) -1- (5-fluoro-2-pyridyl) ethyl] amino] -6 - [(5-isopropoxy-1H-pyrazol-3-yl) amino] pyridin -3-carbonitrile ?.
US9567386B2 (en)2010-08-172017-02-14Ambrx, Inc.Therapeutic uses of modified relaxin polypeptides
HUE045845T2 (en)2010-08-172021-12-28Ambrx Inc Modified relaxin polypeptides and their use
US9416221B2 (en)2010-08-302016-08-16Surmodics, Inc.Biodegradable terpolymers and terpolymer blends as pressure-sensitive adhesives
US9616097B2 (en)2010-09-152017-04-11Synergy Pharmaceuticals, Inc.Formulations of guanylate cyclase C agonists and methods of use
TWI480288B (en)2010-09-232015-04-11Lilly Co EliFormulations for bovine granulocyte colony stimulating factor and variants thereof
CA2813203C (en)2010-09-282022-10-18Sekisui Chemical Co., Ltd.Anti-human ccr7 antibody, hybridoma, nucleic acid, vector, cell, pharmaceutical composition, and antibody-immobilized carrier
US9572907B2 (en)2010-10-012017-02-21Covidien LpImplantable polymeric films
JP2013538856A (en)2010-10-012013-10-17バイオジェン・アイデック・エムエイ・インコーポレイテッド How to use interferon beta alone or in combination with other cancer treatments
US8920867B2 (en)2010-10-192014-12-30Covidien LpMethods of forming self-supporting films for delivery of therapeutic agents
US8632839B2 (en)2010-10-192014-01-21Covidien LpMethods of forming self-supporting films for delivery of therapeutic agents
US9861590B2 (en)2010-10-192018-01-09Covidien LpSelf-supporting films for delivery of therapeutic agents
AU2011323784A1 (en)2010-10-252013-05-30Regents Of The University Of MinnesotaTherapeutic composition for treatment of glioblastoma
EP2632951B1 (en)2010-10-272017-08-02Amgen Inc.Dkk1 antibodies and methods of use
SG10201508981YA (en)2010-11-012015-11-27Peptimed IncCompositions Of A Peptide-Based System For Cell-Specific Targeting
TWI629355B (en)2010-11-172018-07-11中外製藥股份有限公司 Multispecific antigen-binding molecule capable of replacing blood coagulation factor VIII
GB201019467D0 (en)2010-11-172010-12-29Biotecnol SaTherapeutic agent
US9023791B2 (en)2010-11-192015-05-05Novartis AgFibroblast growth factor 21 mutations
AU2011332007C1 (en)2010-11-242017-03-02Lexicon Pharmaceuticals, Inc.Antibodies to Notum Pectinacetylesterase
KR20240025059A (en)2010-11-302024-02-26추가이 세이야쿠 가부시키가이샤Cytotoxicity-inducing therapeutic agent
KR101185310B1 (en)2010-12-232012-09-21한올바이오파마주식회사Modified human tumor necrosis factor receptor-1 polypeptides or fragments thereof and method for preparing the same
WO2012092539A2 (en)2010-12-312012-07-05Takeda Pharmaceutical Company LimitedAntibodies to dll4 and uses thereof
US9144634B2 (en)2011-01-142015-09-29Covidien LpMedical device with intrapore films
WO2012102679A1 (en)2011-01-242012-08-02National University Of SingaporePathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
AU2012209466C1 (en)2011-01-272016-06-23Neuren Pharmaceuticals LimitedTreatment of Autism Spectrum Disorders using Glycyl-L-2-Methylprolyl-L-Glutamic Acid
WO2012118903A2 (en)2011-03-012012-09-07Amgen Inc.Bispecific binding agents
BR112013023120A2 (en)2011-03-102017-09-19Genentech Inc method of treating a dysfunction associated with altered vascular barrier function in a subject, method of reducing or inhibiting vascular barrier function in a subject in need thereof and method of treating a dysfunction requiring formation of new blood vessels in a subject
MX356426B (en)2011-04-042018-05-29Univ Iowa Res FoundMethods of improving vaccine immunogenicity.
SG194111A1 (en)2011-04-072013-11-29Amgen IncNovel egfr binding proteins
CN103533951B (en)2011-04-082017-04-19安姆根有限公司Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15)
JP5728128B2 (en)2011-04-252015-06-03シャントン ルーイエ ファーマシューティカル カンパニー リミテッド Risperidone sustained release microsphere composition
MX389061B (en)2011-04-292025-03-20Univ Washington THERAPEUTIC NUCLEASE COMPOSITIONS AND METHODS.
MX2013012716A (en)2011-05-032014-03-21Genentech IncVascular disruption agents and uses thereof.
DK2705013T3 (en)2011-05-042016-07-18Balance Therapeutics IncPentylenetetrazolderivater
CA2835101A1 (en)2011-05-102012-11-15Amgen Inc.Method of identifying compounds that specifically modulate the interaction of fgfr1 and .beta.-klotho
JOP20200043A1 (en)2011-05-102017-06-16Amgen Inc Ways to treat or prevent cholesterol disorders
CN108840912B (en)2011-05-112023-07-04儿童医疗中心有限公司 Modified biotin-binding protein and its fusion protein and application
US9574002B2 (en)2011-06-062017-02-21Amgen Inc.Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
WO2012174064A1 (en)2011-06-142012-12-20Bikam Pharmaceuticals, Inc.Opsin-binding ligands, compositions and methods of use
CA2838340A1 (en)2011-06-172012-12-20Amgen Inc.Method of treating or ameliorating metabolic disorders using clec-2
FR2977790B1 (en)2011-07-132013-07-19Sofradim Production PROSTHETIC FOR UMBILIC HERNIA
US20140234330A1 (en)2011-07-222014-08-21Amgen Inc.Il-17 receptor a is required for il-17c biology
US8579924B2 (en)2011-07-262013-11-12Covidien LpImplantable devices including a mesh and a pivotable film
WO2013017656A1 (en)2011-08-022013-02-07Medizinische Universität WienAntagonists of ribonucleases for treating obesity
US9328386B2 (en)2011-08-162016-05-03Evotec (München) GmbhMarkers for susceptibility to an inhibitor of an Src-family kinase
EP3348575A1 (en)2011-08-162018-07-18Emory UniversityJaml specific binding agents, antibodies, and uses related thereto
US9745288B2 (en)2011-08-162017-08-29Indiana University Research And Technology CorporationCompounds and methods for treating cancer by inhibiting the urokinase receptor
US9701731B2 (en)2011-08-192017-07-11Children's Medical Center CorporationVEGF-binding protein for blockade of angiogenesis
US9782957B2 (en)2011-08-242017-10-10Covidien LpMedical device films
CA2845357A1 (en)2011-08-312013-03-07Amgen Inc.Method of treating or ameliorating type 1 diabetes using fgf21
WO2013039916A1 (en)2011-09-122013-03-21The United States Of America, Represented By The Secretary, Dept. Of Health And Human ServicesCompositions for and methods of treatment and enhanced detection of non-pituitary tumors
JP6251678B2 (en)2011-09-222017-12-20アムジエン・インコーポレーテツド CD27L antigen binding protein
US9458214B2 (en)2011-09-262016-10-04Novartis AgDual function fibroblast growth factor 21 proteins
JO3476B1 (en)2011-09-262020-07-05Novartis AgFusion proteins for treating metabolic disorders
KR102366029B1 (en)2011-09-302022-02-23추가이 세이야쿠 가부시키가이샤Antigen-binding molecule inducing immune response to target antigen
DE102011114864A1 (en)2011-10-052013-04-11Acino Ag Process for producing a homogeneous powder mixture and method for producing an implant and implant
WO2013053076A1 (en)2011-10-102013-04-18Zensun （Shanghai）Science & Technology LimitedCompositions and methods for treating heart failure
WO2013056255A1 (en)2011-10-142013-04-18The Board Of Trustees Of The University Of IllinoisMethods and compositions for inhibiting tumor cell proliferation
US8906860B2 (en)2011-10-142014-12-09The Board Of Trustees Of The University Of IllinoisMethods and compositions inhibiting tumor cell proliferation
AU2012325341B2 (en)2011-10-192017-01-05Bikam Pharmaceuticals, Inc.Opsin-binding ligands, compositions and methods of use
US8932621B2 (en)2011-10-252015-01-13Covidien LpImplantable film/mesh composite
US9179994B2 (en)2011-10-252015-11-10Covidien LpImplantable film/mesh composite
US9005308B2 (en)2011-10-252015-04-14Covidien LpImplantable film/mesh composite for passage of tissue therebetween
TWI679212B (en)2011-11-152019-12-11美商安進股份有限公司Binding molecules for e3 of bcma and cd3
AU2012340174A1 (en)2011-11-162014-05-29Amgen Inc.Methods of treating epidermal growth factor deletion mutant VIII related disorders
GR1007832B (en)2011-11-212013-02-14Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων,Activin neutralisers and uses thereof for treatment of diseases associated with aberrant "host defence response" activation
CN104185420B (en)2011-11-302017-06-09埃默里大学 Antiviral JAK inhibitors for the treatment or prevention of retroviral and other viral infections
BR112014012997A2 (en)2011-11-302017-06-13Bikam Pharmaceuticals Inc opsin binding binders, compositions and methods of use
WO2013081642A1 (en)2011-12-012013-06-06Bikam Pharmaceuticals, Inc.Opsin-binding ligands, compositions and methods of use
MX368200B (en)2011-12-082019-09-24Amgen IncAgonistic human lcat antigen binding proteins and their use in therapy.
EP2788500A1 (en)2011-12-092014-10-15F.Hoffmann-La Roche AgIdentification of non-responders to her2 inhibitors
EP2794657B1 (en)2011-12-192017-10-11Xoma (Us) LlcMethods for treating acne
EP2793921B1 (en)2011-12-222019-04-24Children's Medical Center CorporationSaposin-a derived peptides and uses thereof
CN104411717A (en)2012-01-092015-03-11斯克利普斯研究所Humanized antibodies with ultralong CDR3S
JP6684490B2 (en)2012-01-092020-04-22ザ・スクリップス・リサーチ・インスティテュート Ultralong complementarity determining regions and uses thereof
EP2802602B1 (en)2012-01-112019-03-27Arizona Board of Regents, a Body Corporate of the State of Arizona acting for and on behalf of Arizona State UniversityBispecific antibody fragments for neurological disease proteins and methods of use
EA201491413A1 (en)2012-01-262015-03-31Эмджен Инк. POLYPEPTIDE GROWTH FACTOR AND DIFFERENTIATION 15 (GDF-15)
EP2626066A1 (en)2012-02-102013-08-14Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.Combination therapy comprising selective VEGFR-2 inhibitors and MEK inhibitors
JP6216766B2 (en)2012-03-292017-10-18ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ Click nucleic acid
US10206769B2 (en)2012-03-302019-02-19Covidien LpImplantable devices including a film providing folding characteristics
US8753643B1 (en)2012-04-112014-06-17Life-Science Innovations, LlcSpray dried compositions and methods of use
WO2013155504A1 (en)2012-04-142013-10-17Intra-Cellular Therapies, Inc.Novel methods
US20150118237A1 (en)2012-04-232015-04-30Genefrontier CorporationAnti-human cd69 antibody, and use thereof for medical purposes
EA039663B1 (en)2012-05-032022-02-24Амген Инк.Use of an anti-pcsk9 antibody for lowering serum cholesterol ldl and treating cholesterol related disorders
WO2013173364A2 (en)2012-05-142013-11-21Biogen Idec Ma Inc.Lingo-2 antagonists for treatment of conditions involving motor neurons
AR091069A1 (en)2012-05-182014-12-30Amgen Inc PROTEINS OF UNION TO ANTIGEN DIRECTED AGAINST THE ST2 RECEIVER
WO2013177187A2 (en)2012-05-222013-11-28Massachusetts Institute Of TechnologySynergistic tumor treatment with extended-pk il-2 and therapeutic agents
FR2992662B1 (en)2012-06-282014-08-08Sofradim Production KNIT WITH PICOTS
FR2992547B1 (en)2012-06-292015-04-24Sofradim Production PROSTHETIC FOR HERNIA
WO2014006063A2 (en)2012-07-022014-01-09Medizinische Universität WienComplement split product c4d for the treatment of inflammatory conditions
EP2687225A1 (en)2012-07-192014-01-22Alfact InnovationHIP/PAP protein and derivatives thereof for use in treating cancer
SI3715345T1 (en)2012-07-252024-07-31Bausch + Lomb Ireland Limited PREPARATION OF THE LFA-1 INHIBITOR
DE102013011399A1 (en)2012-07-312014-02-06Amw GmbhRod-shaped biodegradable implant useful for maintenance therapy in schizophrenia in patients comprises risperidone
EP2695950A1 (en)2012-08-102014-02-12Blackfield AGMarkers for responsiveness to an inhibitor of the fibroblast growth factor receptor
EP2887942A4 (en)2012-08-212016-08-31Genesys Res Inst COMPOSITIONS AND METHODS FOR TREATMENT OR PREVENTION OF ANTHRACYCLIN-INDUCED CARDIOTOXICITY
ES2703913T3 (en)2012-10-172019-03-13Vascular Biogenics Ltd Treatment methods that use adenovirus
US9309318B2 (en)2012-10-172016-04-12Amgen, Inc.Compositions relating to anti-IL-21 receptor antibodies
AU2013342779B2 (en)2012-11-092019-09-26Genefrontier CorporationAnti-ADAM28 antibody for treating cancer
UY35148A (en)2012-11-212014-05-30Amgen Inc HETERODIMERIC IMMUNOGLOBULINS
BR112015012644A2 (en)2012-11-302017-12-19Hoffmann La Roche method for determining a cancer patient's need, cancer treatment method, pharmaceutical composition, use of a nucleic acid or antibody and kit;
TW201425336A (en)2012-12-072014-07-01Amgen IncBCMA antigen binding proteins
EP2934588A4 (en)2012-12-202016-09-28Medimmune LlcLiquid antibody formulation with improved aggregation properties
JO3519B1 (en)2013-01-252020-07-05Amgen Inc Antibody combinations for CDH19 and CD3
EP2948478B1 (en)2013-01-252019-04-03Amgen Inc.Antibodies targeting cdh19 for melanoma
CN105431455A (en)2013-02-012016-03-23圣塔玛丽亚生物疗法公司 Administration of Anti-Activin A Compounds to Subjects
ES2959258T3 (en)2013-02-072024-02-22Childrens Medical Center Protein antigens that provide protection against pneumococcal colonization and/or disease
AU2014218599C1 (en)2013-02-252018-09-06Bausch Health Ireland LimitedGuanylate cyclase receptor agonists for use in colonic cleansing
US20140308352A1 (en)2013-03-112014-10-16Zogenix Inc.Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
CN115804749A (en)2013-03-112023-03-17度瑞公司 Injectable Controlled Release Compositions Comprising High Viscosity Liquid Carriers
US9458246B2 (en)2013-03-132016-10-04Amgen Inc.Proteins specific for BAFF and B7RP1
PH12022550138A1 (en)2013-03-132023-03-06Amgen IncProteins specific for baff and b7rp1 and uses thereof
AU2014244444A1 (en)2013-03-142015-09-24Amgen Inc.CHRDL-1 antigen binding proteins and methods of treatment
US9580486B2 (en)2013-03-142017-02-28Amgen Inc.Interleukin-2 muteins for the expansion of T-regulatory cells
US9676851B2 (en)2013-03-152017-06-13Amgen Inc.Human PAC1 antibodies
WO2014145192A1 (en)2013-03-152014-09-18Intra-Cellular Therapies, Inc.Organic compounds
PL2970449T3 (en)2013-03-152020-04-30Amgen Research (Munich) GmbhSingle chain binding molecules comprising n-terminal abp
WO2014151200A2 (en)2013-03-152014-09-25Synergy Pharmaceuticals Inc.Compositions useful for the treatment of gastrointestinal disorders
US9850297B2 (en)2013-03-152017-12-26Amgen Inc.Secreted frizzle-related protein 5 (SFRP5) binding proteins
EP2970384A1 (en)2013-03-152016-01-20Synergy Pharmaceuticals Inc.Agonists of guanylate cyclase and their uses
US9555113B2 (en)2013-03-152017-01-31Durect CorporationCompositions with a rheological modifier to reduce dissolution variability
EP2970446A1 (en)2013-03-152016-01-20Amgen Research (Munich) GmbHAntibody constructs for influenza m2 and cd3
EP2968480B1 (en)2013-03-152020-10-14Amgen Inc.Treating metabolic disorders using pla2g12a polypeptides and pla2g12a mutant polypeptides
JP6469644B2 (en)2013-03-152019-02-13アムジエン・インコーポレーテツド Methods and compositions related to anti-CCR7 antigen binding proteins
US9708375B2 (en)2013-03-152017-07-18Amgen Inc.Inhibitory polypeptides specific to WNT inhibitors
JP6151848B2 (en)*2013-04-182017-06-21シャンドン ルイ ファーマシューティカル カンパニー リミテッド Goserelin sustained-release microsphere pharmaceutical composition
WO2014187881A1 (en)2013-05-212014-11-27Max-Planck Gesellschaft zur Förderung der Wissenschaften e.V.Isoforms of gata6 and nkx2-1 as markers for diagnosis and therapy of cancer and as targets for anti-cancer therapy
EP3610905B1 (en)2013-05-222021-03-31Zensun (Shanghai) Science & Technology, Co., Ltd.Extended release of neuregulin for treating heart failure
US20160130585A1 (en)2013-05-282016-05-12The Johns Hopkins UniversityAptamers for the treatment of sickle cell disease
ES2895824T3 (en)2013-05-302022-02-22Kiniksa Pharmaceuticals Ltd Oncastatin M receptor antigen-binding proteins
EP2810648A1 (en)2013-06-042014-12-10Daniel RauhTargeting domain-domain interaction for the identification of kinase modulators
JP6442404B2 (en)2013-06-112018-12-19国立研究開発法人国立精神・神経医療研究センター Method for predicting treatment prognosis in patients with relapsing-remitting multiple sclerosis (RRMS), and method for determining new treatment indication
EP3007704B1 (en)2013-06-132021-01-06Antisense Therapeutics LtdCombination therapy for acromegaly
WO2014204933A1 (en)2013-06-172014-12-24Adamas Pharmaceuticals, Inc.Amantadine compositions and methods of use
EP2835135A3 (en)2013-06-192015-06-24Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. BerlinMeans and methods for treating pseudomonas infection
EP3013422A1 (en)2013-06-282016-05-04Amgen Inc.Methods for treating homozygous familial hypercholesterolemia
WO2015017146A2 (en)2013-07-182015-02-05Fabrus, Inc.Antibodies with ultralong complementarity determining regions
CN105814074B (en)2013-07-182020-04-21图鲁斯生物科学有限责任公司 Humanized antibodies with ultralong complementarity determining regions
KR102376451B1 (en)2013-07-312022-03-23암젠 인크Growth differentiation factor 15 (gdf-15) constructs
WO2015022326A1 (en)2013-08-122015-02-19Xiber Science GmbhPeptides as active agents for treating primary graft dysfunction
TW201605896A (en)2013-08-302016-02-16安美基股份有限公司GITR antigen binding proteins
CA2923145A1 (en)2013-09-052015-03-12Amgen Inc.Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
CA2923835C (en)2013-09-112022-11-29The Administrators Of The Tulane Educational FundNovel anthranilic amides and the use thereof
CA2924109A1 (en)2013-09-132015-03-19The California Institute For Biomedical ResearchModified therapeutic agents and compositions thereof
TWI688401B (en)2013-09-132020-03-21美商安進公司Combination of epigenetic factors and bispecific compounds targeting cd33 and cd3 in the treatment of myeloid leukemia
DK2808338T3 (en)2013-09-162016-06-06Cemm - Forschungszentrum Für Molekulare Medizin GmbhMutant calreticulin for diagnosis of myeloid malignancies
GB201316738D0 (en)2013-09-202013-11-06Rainbow Medical Engineering LtdImplantable Medical Devices
JP6445440B2 (en)2013-09-202018-12-26中外製薬株式会社 Treatment of bleeding disorders with anti-protein C antibodies
US9957506B2 (en)2013-09-252018-05-01Cornell UniversityCompounds for inducing anti-tumor immunity and methods thereof
EP3052102B1 (en)2013-10-042019-12-04Aptose Biosciences Inc.Compositions for treating cancers
AU2014331704A1 (en)2013-10-102016-04-28Synergy Pharmaceuticals, Inc.Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
KR102357968B1 (en)2013-10-152022-02-03더 스크립스 리서치 인스티튜트Chimeric antigen receptor t cell switches and uses thereof
JP6734774B2 (en)2013-10-152020-08-05ザ スクリプス リサーチ インスティテュート Peptide chimeric antigen receptor T cell switch and uses thereof
AU2014335251B2 (en)2013-10-152020-04-30Genefrontier CorporationHuman antibody against aggrecanase-type ADAMTS species for therapeutics of aggrecanase-related diseases
US20160235810A1 (en)2013-10-182016-08-18Novartis AgMethods of treating diabetes and related disorders
JP6495270B2 (en)2013-10-302019-04-03ザ ユニバーシティ オブ ウェスタン オーストラリア Pharmaceutical composition containing a neuroprotective peptide
PL3063275T3 (en)2013-10-312020-03-31Resolve Therapeutics, LlcTherapeutic nuclease-albumin fusions and methods
GB201319374D0 (en)2013-11-012013-12-18Univ NottinghamGlycans as functional cancer targets abd antibodies thereto
CN105939712A (en)2013-12-032016-09-14细胞内治疗公司 new method
WO2015095406A1 (en)2013-12-182015-06-25The California Institute For Biomedical ResearchModified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
CN103965357B (en)2013-12-312016-08-17嘉和生物药业有限公司A kind of anti-human RANKL antibody
WO2015110930A1 (en)2014-01-242015-07-30Pfizer Inc.Modified interleukin 21 receptor proteins
WO2015120187A1 (en)2014-02-052015-08-13The University Of ChicagoChimeric antigen receptors recognizing cancer-spevific tn glycopeptide variants
EP3104873B1 (en)2014-02-132019-09-04Technische Universität MünchenFgf-8 for use in treating diseases or disorders of energy homeostasis
CA3177696A1 (en)2014-02-202015-08-27Allergan, Inc.Complement component c5 antibodies
US9796776B2 (en)2014-02-272017-10-24Allergan, Inc.Complement factor Bb antibodies
CN106458856A (en)2014-03-072017-02-22约翰霍普金斯大学Inhibitors of histone lysine specific demethylase (lsd1) and histone deacetylases (hdacs)
EP3116861B1 (en)2014-03-142020-12-16The University of North Carolina at Chapel HillSmall molecules for inhibiting male fertility
EP3125938A4 (en)2014-03-312017-08-23The Johns Hopkins UniversityUse of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-ctla-4 and/or anti-pd-1 antibodies to treat solid tumor malignancies
US9745300B2 (en)2014-04-042017-08-29Intra-Cellular Therapies, Inc.Organic compounds
KR20170012210A (en)2014-04-042017-02-02인트라-셀룰라 써래피스, 인코퍼레이티드.Organic compounds
CA2888068A1 (en)2014-04-152015-10-15The Hospital For Sick ChildrenCationic antimicrobial peptides
US9956164B2 (en)2014-04-162018-05-01Veyx-Pharma GmbhVeterinary pharmaceutical composition and use thereof
US20170073690A1 (en)2014-05-152017-03-16CEMM - Forschungzentrum Fuer Molekulare Medizin GMBHAntagonists of slc38a9 and their use in therapy
WO2015179415A1 (en)2014-05-192015-11-26Novartis AgMethods of treating anorexia
WO2015184260A2 (en)2014-05-302015-12-03The Johns Hopkins UniversityMethods for treating mendelian disorders of the epigenetic machinery
CA2950840C (en)2014-06-032023-09-26Xbiotech Inc.Compositions and methods for treating and preventing staphylococcus aureus infections
US10179776B2 (en)2014-06-092019-01-15Intra-Cellular Therapies, Inc.Compounds and methods of use to treat schizophrenia
EP3151859B1 (en)2014-06-092020-11-25Ultragenyx Pharmaceutical Inc.The effective and efficient control of serum phosphate for optimal bone formation
TN2016000551A1 (en)2014-06-132018-04-04Amgen IncFormulated receptor polypeptides and related methods
TW201625299A (en)2014-06-202016-07-16Chugai Pharmaceutical Co Ltd Medicinal composition for the prevention and/or treatment of a disease which is afflicted and/or progressed due to a decrease or deficiency of the activity of the VIII clotting factor and/or the activated VIII clotting factor
US10166304B2 (en)2014-07-112019-01-01Regents Of The University Of MinnesotaAntibody fragments for detecting cancer and methods of use
EP2977758A1 (en)2014-07-242016-01-27Université De Nice Sophia AntipolisMethods and kits for monitoring membranous nephropathy
UY36245A (en)2014-07-312016-01-29Amgen Res Munich Gmbh ANTIBODY CONSTRUCTS FOR CDH19 AND CD3
AU2015294834B2 (en)2014-07-312021-04-29Amgen Research (Munich) GmbhOptimized cross-species specific bispecific single chain antibody constructs
US10166273B2 (en)2014-08-122019-01-01The Board Of Trustees Of The Leland Stanford Junior UniversitySynergistic tumor treatment with antibodies targeting PD-1, PD-L1 or CTLA4 and integrin-binding-Fc-fusion protein
US20170224777A1 (en)2014-08-122017-08-10Massachusetts Institute Of TechnologySynergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
JP6683686B2 (en)2014-08-222020-04-22オークランド ユニサービシーズ リミティド Channel regulator
JP2017530948A (en)2014-08-272017-10-19ペプティメド， インコーポレイテッド Anti-tumor compositions and methods
WO2016040767A2 (en)2014-09-122016-03-17Amgen Inc.Chrdl-1 epitopes and antibodies
JP6821560B2 (en)2014-10-212021-01-27サイクロン ファーマシューティカルズ インターナショナル エルティーディー．Ｓｃｉｃｌｏｎｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｔｄ． Cancer treatment with immunostimulants
PE20170950A1 (en)2014-10-242017-07-13Bristol Myers Squibb Co MODIFIED FIBROBLAST GROWTH FACTOR 2 (FGF-21) POLYEPTIDES AND USES OF THE SAME
WO2016069889A1 (en)2014-10-312016-05-06Resolve Therapeutics, LlcTherapeutic nuclease-transferrin fusions and methods
WO2016079321A1 (en)2014-11-202016-05-26Cemm Forschungszentrum Für Molekulare Medizin GmbhAntagonists of setdb2 for use in the therapy of infectious diseases
EP3085709B1 (en)2014-12-282019-08-21Genor Biopharma Co., LtdHumanized anti-human rankl antibody, pharmaceutical composition and use thereof
AU2016205197B2 (en)2015-01-082021-10-21Biogen Ma Inc.LINGO-1 antagonists and uses for treatment of demyelinating disorders
US20180170992A1 (en)2015-01-262018-06-21The University Of ChicagoCAR T CELLS RECOGNIZING CANCER-SPECIFIC IL 13Ra2
JP7264592B2 (en)2015-01-262023-04-25ザ ユニバーシティー オブ シカゴ IL13Rα2 BINDING AGENTS AND THEIR USE IN CANCER THERAPY
US9375478B1 (en)2015-01-302016-06-28Par Pharmaceutical, Inc.Vasopressin formulations for use in treatment of hypotension
RU2722832C2 (en)2015-02-232020-06-04Сигалл Терапьютикс СасNon-natural class 3 semaphorins and their medical application
US10800828B2 (en)2015-03-262020-10-13The Scripps Research InstituteSwitchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
MY188430A (en)2015-04-102021-12-08Amgen IncInterleukin-2 muteins for the expansion of t-regulatory cells
WO2016168773A2 (en)2015-04-152016-10-20The California Institute For Biomedical ResearchOptimized pne-based chimeric receptor t cell switches and uses thereof
TWI772258B (en)2015-04-172022-08-01德商安美基研究（慕尼黑）公司Bispecific antibody constructs for cdh3 and cd3
WO2016186977A1 (en)2015-05-152016-11-24The Johns Hopkins UniversityNovel fluoride prenatal dietary supplement
US20160361380A1 (en)2015-06-122016-12-15Nymox CorporationCombination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
WO2016205488A1 (en)2015-06-172016-12-22The California Institute For Biomedical ResearchModified therapeutic agents and compositions thereof
US10676490B2 (en)2015-07-072020-06-09Florida Southwestern State CollegeUse of amine carboxyboranes as therapeutic delivery of carbon monoxide and as general drug delivery system in the presence of reactive oxygen species
ES2546566B2 (en)*2015-07-232016-09-14Universidade De Santiago De Compostela System for the administration of biologically active substances prepared by foaming techniques using compressed gases or supercritical fluids
CN108348492B (en)2015-07-312021-09-28约翰霍普金斯大学Methods for cancer and immunotherapy using glutamine analogs
TW202346349A (en)2015-07-312023-12-01德商安美基研究（慕尼黑）公司Antibody constructs for dll3 and cd3
TWI796283B (en)2015-07-312023-03-21德商安美基研究（慕尼黑）公司Antibody constructs for msln and cd3
US10842763B2 (en)2015-07-312020-11-24The Johns Hopkins UniversityMethods for cancer and immunotherapy using prodrugs of glutamine analogs
WO2017023774A1 (en)2015-07-312017-02-09The Johns Hopkins UniversityProdrugs of glutamine analogs
TWI829617B (en)2015-07-312024-01-21德商安美基研究（慕尼黑）公司Antibody constructs for flt3 and cd3
TWI744242B (en)2015-07-312021-11-01德商安美基研究（慕尼黑）公司Antibody constructs for egfrviii and cd3
TWI717375B (en)2015-07-312021-02-01德商安美基研究（慕尼黑）公司Antibody constructs for cd70 and cd3
EP3328374A4 (en)2015-07-312019-03-13The Johns Hopkins University GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS
JO3620B1 (en)2015-08-052020-08-27Amgen Res Munich Gmbh Immunological check point inhibitors for use in the treatment of blood-borne cancers
MX2018004041A (en)2015-10-012018-11-09Amgen IncTreatment of bile acid disorders.
JP6902185B2 (en)2015-11-032021-07-14リージェンツ オブ ザ ユニバーシティ オブ ミネソタ CD200 inhibitor and how to use it
SG10201913746RA (en)2015-11-032020-03-30Ambrx IncAnti-cd3-folate conjugates and their uses
EP3371222A1 (en)2015-11-032018-09-12GlycoMimetics, Inc.Methods and compositions for the production of monoclonal antibodies, hematopoietic stem cells, and methods of using the same
JP6931329B2 (en)2015-11-182021-09-01中外製薬株式会社 Combination therapy using T cell redirection antigen-binding molecule for cells with immunosuppressive function
EP3378488A4 (en)2015-11-182019-10-30Chugai Seiyaku Kabushiki Kaisha METHOD FOR ENHANCING THE HUMORAL IMMUNE RESPONSE
WO2017096262A1 (en)2015-12-042017-06-08Jomoco, Corp.Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
CN108778320A (en)2015-12-182018-11-09泰伦基国际有限公司A novel method for preventing and treating cardiovascular diseases
UA127495C2 (en)2015-12-232023-09-13Амджен Інк. ISOLATED ANTIGEN-BINDING PROTEIN THAT SPECIFICALLY BINDS TO HUMAN GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR) POLYPEPTIDE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
JP6954842B2 (en)2015-12-252021-10-27中外製薬株式会社 Antibodies with enhanced activity and methods for modifying them
JP2019506383A (en)2016-01-112019-03-07シナジー ファーマシューティカルズ インコーポレイテッド Formulations and methods for treating ulcerative colitis
JOP20170017B1 (en)2016-01-252021-08-17Amgen Res Munich GmbhPharmaceutical composition comprising bispecific antibody constructs
KR20240170975A (en)2016-01-262024-12-05인트라-셀룰라 써래피스, 인코퍼레이티드.Organic compounds
LT3411402T (en)2016-02-032022-01-25Amgen Research (Munich) GmbhBcma and cd3 bispecific t cell engaging antibody constructs
EA039859B1 (en)2016-02-032022-03-21Эмджен Рисерч (Мюник) ГмбхBispecific antibody constructs binding egfrviii and cd3
DK3411404T3 (en)2016-02-032023-01-30Amgen Res Munich Gmbh PSMA-AND CD3-BISPECIFIC T CELL-ENGINEERING ANTIBODY CONSTRUCTS
US10098909B2 (en)2016-02-052018-10-16University Of South FloridaIonic cocrystal of lithium, lispro, for the treatment of fragile X syndrome
ES2970828T3 (en)2016-02-102024-05-30Univ Rutgers New anti-lam antibodies
EP3216458A1 (en)2016-03-072017-09-13Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.Modified vascular endothelial growth factor a (vegf-a) and its medical use
SG11201807936VA (en)2016-03-142018-10-30Chugai Pharmaceutical Co LtdCell injury inducing therapeutic drug for use in cancer therapy
ES2879888T3 (en)2016-03-252021-11-23Intra Cellular Therapies Inc Organic compounds and their use in the treatment or prevention of disorders of the central nervous system
EP3436083A4 (en)2016-03-282019-11-27Intra-Cellular Therapies, Inc. NEW COMPOSITIONS AND METHODS
EP3808764A1 (en)2016-05-042021-04-21Amgen Inc.Interleukin-2 muteins for the expansion of t-regulatory cells
US10183058B2 (en)2016-06-172019-01-22Nymox CorporationMethod of preventing or reducing the progression of prostate cancer
CN119120423A (en)2016-07-012024-12-13分解治疗有限责任公司 Optimized dinuclease fusions and methods
CA3028450A1 (en)2016-07-062018-01-11Durect CorporationOral dosage form with drug composition, barrier layer and drug layer
US10300145B2 (en)2016-07-152019-05-28Massachusetts Institute Of TechnologySynthetic nanoparticles for delivery of immunomodulatory compounds
US10172910B2 (en)2016-07-282019-01-08Nymox CorporationMethod of preventing or reducing the incidence of acute urinary retention
CA3032348A1 (en)2016-08-082018-02-15Amgen Inc.Method of improving connective tissue attachment using anti-sclerostin antibodies
US10981976B2 (en)2016-08-312021-04-20University Of RochesterHuman monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
BR112019003989A2 (en)2016-09-062019-05-28Chugai Pharmaceutical Co Ltd methods of using a bispecific antibody that recognizes coagulation factor ix and / or activated coagulation factor ix and coagulation factor x and / or coagulation factor x activated
US10532081B2 (en)2016-09-072020-01-14Nymox CorporationMethod of ameliorating or preventing the worsening or the progression of symptoms of BPH
CN109790125B (en)2016-09-162022-07-05研究三角协会 Tetrahydroisoquinoline kappa opioid antagonists
EP3525763B1 (en)2016-10-122025-03-05Intra-Cellular Therapies, Inc.Amorphous solid dispersions
KR102613430B1 (en)2016-10-192023-12-18더 스크립스 리서치 인스티튜트 Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor-interacting domains and uses thereof
US20190328850A1 (en)2016-12-152019-10-31Talengen International LimitedMethod for preventing and treating lipid metabolism disorders and related diseases thereof
WO2018108161A1 (en)2016-12-152018-06-21深圳瑞健生命科学研究院有限公司Method and drug for preventing and treating obesity
TWI642442B (en)2016-12-152018-12-01深圳瑞健生命科學硏究院有限公司 Use of plasminogen for preparing medicine for reducing glucagon secretion
US20190365871A1 (en)2016-12-152019-12-05Talengen International LimitedDrug for preventing and treating osteoporosis and uses thereof
US11389515B2 (en)2016-12-152022-07-19Talengen International LimitedMethod for mitigating heart disease
US11219669B2 (en)2016-12-152022-01-11Talengen International LimitedMethod for preventing and treating liver fibrosis
EP3556388A4 (en)2016-12-152020-07-08Talengen International LimitedMethod for preventing and treating pathological renal tissue injury
WO2018126140A1 (en)2016-12-292018-07-05Intra-Cellular Therapies, Inc.Organic compounds
US10906906B2 (en)2016-12-292021-02-02Intra-Cellular Therapies, Inc.Organic compounds
WO2018128454A1 (en)2017-01-062018-07-12에이비엘바이오 주식회사ANTI-α-SYN ANTIBODY AND USE THEREOF
MX2019008029A (en)2017-01-062019-12-11Abl Bio IncANTI-a-SYN ANTIBODY AND USE THEREOF.
US11529391B2 (en)2017-01-092022-12-20The Board Of Trustees Of The Leland Stanford Junior UniversityReversing deficient hedgehog signaling restores deficient skeletal regeneration
WO2018132516A1 (en)2017-01-102018-07-19Nodus TherapeuticsCombination tumor treatment with an integrin-binding-fc fusion protein and immune modulator
US10350266B2 (en)2017-01-102019-07-16Nodus Therapeutics, Inc.Method of treating cancer with a multiple integrin binding Fc fusion protein
EP4364799A3 (en)2017-01-112024-07-17Paracelsus Medizinische Privatuniversität Salzburg - PrivatstiftungMesenchymal stem cell-derived extracellular vesicles and their medical use
JOP20190177A1 (en)2017-01-172019-07-16Amgen IncMethod of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)
JOP20190189A1 (en)2017-02-022019-08-01Amgen Res Munich GmbhLow ph pharmaceutical composition comprising t cell engaging antibody constructs
CA3052639A1 (en)2017-02-082018-08-16Bristol-Myers Squibb CompanyModified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
US10335453B2 (en)2017-03-012019-07-02Nymox CorporationCompositions and methods for improving sexual function
US11021529B2 (en)2017-03-032021-06-01Massachusetts Institute Of TechnologyAntimicrobial constructs and uses thereof
US10421968B2 (en)2017-03-152019-09-24Versitech LimitedAmphiphilic dendrimers complexed with siRNA for treatment of cancer
IL268970B2 (en)2017-03-242023-12-01Intra Cellular Therapies IncOral transmucosal formulations of substituted heterocycle fused gamma carbolines
CN110691973B (en)2017-04-252024-11-29普罗瑟拉生物公司Methods for quantifying meta alpha inhibitor proteins
US11851486B2 (en)2017-05-022023-12-26National Center Of Neurology And PsychiatryMethod for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
AU2018263087B2 (en)2017-05-042021-12-16Helsingin YliopistoC-terminal CDNF and manf fragments, pharmaceutical compositions comprising same and uses thereof
US11918650B2 (en)2017-05-052024-03-05Amgen Inc.Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
CA3062749A1 (en)2017-05-122018-11-15Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V.Compounds for use in the treatment or prevention of melanoma
JOP20190259A1 (en)2017-05-312019-10-31Amgen IncAnti-jagged1 antigen binding proteins
WO2018236904A1 (en)2017-06-192018-12-27Surface Oncology, Inc. COMBINATION OF ANTI-CD47 ANTIBODIES AND CELL DEATH INDUCING AGENTS, AND USES THEREOF
TWI714862B (en)2017-06-192021-01-01大陸商深圳瑞健生命科學硏究院有限公司 A method and drug for regulating GLP-1/GLP-1R
CA3062194A1 (en)2017-06-202018-12-27Amgen Inc.Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
SG10201913147WA (en)2017-07-112020-02-27Compass Therapeutics LlcAgonist antibodies that bind human cd137 and uses thereof
JP2020528054A (en)2017-07-192020-09-17オークランド ユニサービシズ リミテッド Cytokine modulation
CA3071119A1 (en)2017-07-262019-01-31Intra-Cellular Therapies, Inc.Substituted heterocycle fused gamma-carbolines for treatment or prophylaxis of central nervous system disorders
CN111093664B (en)2017-07-262023-06-02细胞内治疗公司Organic compound
EP3665202A1 (en)2017-08-092020-06-17Massachusetts Institute Of TechnologyAlbumin binding peptide conjugates and methods thereof
US11485781B2 (en)2017-08-172022-11-01Massachusetts Institute Of TechnologyMultiple specificity binders of CXC chemokines
KR102777015B1 (en)2017-08-222025-03-10사나바이오, 엘엘씨 Availability of interferon receptors and their uses
EP3684408A1 (en)2017-09-192020-07-29Massachusetts Institute of TechnologyCompositions for chimeric antigen receptor t cell therapy and uses thereof
WO2019070901A1 (en)2017-10-042019-04-11Amgen Inc.Transthyretin immunoglobulin fusions
JP7235249B2 (en)2017-10-202023-03-08学校法人兵庫医科大学 Pharmaceutical composition for suppressing postoperative adhesion containing anti-IL-6 receptor antibody
EP3704132A4 (en)2017-10-302021-07-28Enterin, Inc. NEW SOLID FORMS OF SQUALAMINE AND THE METHOD OF MANUFACTURING THEREOF
US11718679B2 (en)2017-10-312023-08-08Compass Therapeutics LlcCD137 antibodies and PD-1 antagonists and uses thereof
US11851497B2 (en)2017-11-202023-12-26Compass Therapeutics LlcCD137 antibodies and tumor antigen-targeting antibodies and uses thereof
CN111315780A (en)2017-12-112020-06-19安进公司 Continuous Manufacturing Process for Bispecific Antibody Products
AU2018385230B2 (en)2017-12-142022-10-13Abl Bio Inc.Bispecific antibody to a-syn/IGF1R and use thereof
WO2019114839A1 (en)2017-12-152019-06-20泰伦基国际有限公司Method and drug for preventing or treating osteoarthritis
EP3727447A1 (en)2017-12-192020-10-28Massachusetts Institute of TechnologyAntigen-adjuvant coupling reagents and methods of use
TWI817974B (en)2017-12-282023-10-11日商中外製藥股份有限公司Cytotoxicity-inducing therapeutic agent
UY38041A (en)2017-12-292019-06-28Amgen Inc CONSTRUCTION OF BIESPECFIC ANTIBODY DIRECTED TO MUC17 AND CD3
TWI822728B (en)2018-01-312023-11-21加藤元一 Asthma therapeutic agents containing IL-6 inhibitors
SG11202007558YA (en)2018-02-092020-09-29Nestle Skin Health SaNemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation
WO2019178269A2 (en)2018-03-142019-09-19Surface Oncology, Inc.Antibodies that bind cd39 and uses thereof
MX2020009668A (en)2018-03-162021-01-08Intra Cellular Therapies IncNovel methods.
WO2019183499A1 (en)2018-03-222019-09-26Surface Oncology, Inc.Anti-il-27 antibodies and uses thereof
WO2019183341A1 (en)2018-03-232019-09-26Intra-Cellular Therapies, Inc.Organic compounds
MX2020009929A (en)2018-03-232021-01-08Intra Cellular Therapies IncOrganic compounds.
EP3774858B1 (en)2018-03-292025-07-30MyNeuroCure OyC-terminal cdnf fragments having neuroprotective effect
IL316596A (en)2018-03-302024-12-01Amgen Inc Variants of the carboxylation rate of antibodies
EP3773656A1 (en)2018-04-092021-02-17Amgen Inc.Growth differentiation factor 15 fusion proteins
WO2019200357A1 (en)2018-04-122019-10-17Surface Oncology, Inc.Biomarker for cd47 targeting therapeutics and uses therefor
CN119286871A (en)2018-04-192025-01-10查美特制药公司 Synthetic RIG-I-like receptor agonists
WO2019207051A1 (en)2018-04-252019-10-31Università Degli Studi Di TorinoMedical use of combinations of non-natural semaphorins 3 and antimetabolites
WO2019226658A1 (en)2018-05-212019-11-28Compass Therapeutics LlcMultispecific antigen-binding compositions and methods of use
TW202003580A (en)2018-05-212020-01-16美商坎伯斯治療有限責任公司Compositions and methods for enhancing the killing of target cells by NK cells
WO2019225777A1 (en)2018-05-232019-11-28에이비엘바이오 주식회사Anti-ror1 antibody and use thereof
WO2019225787A1 (en)2018-05-242019-11-28에이비엘바이오 주식회사Anti-b7-h3 antibody and use thereof
EP3801527B1 (en)2018-06-082025-02-19Intra-Cellular Therapies, Inc.Fused gamma-carbolines for acute treatment of anxiety or depression
WO2019241278A1 (en)2018-06-112019-12-19Intra-Cellular Therapies, Inc.Substituted heterocycle fused gamma-carbolines synthesis
AU2019284362A1 (en)2018-06-112021-01-07University Of Florida Research Foundation, Inc.Materials and methods for treating stress-related disorders and cancer
WO2020011938A1 (en)2018-07-112020-01-16Medizinische Universität WienGlucocorticoids for the topical treatment of autoimmune gastritis
US20220275043A1 (en)2018-07-172022-09-01Massachusetts Institute Of TechnologySoluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
WO2020033925A2 (en)2018-08-092020-02-13Compass Therapeutics LlcAntibodies that bind cd277 and uses thereof
WO2020033923A1 (en)2018-08-092020-02-13Compass Therapeutics LlcAntigen binding agents that bind cd277 and uses thereof
US20210309746A1 (en)2018-08-092021-10-07Compass Therapeutics LlcAntibodies that bind cd277 and uses thereof
US12377294B2 (en)2018-08-282025-08-05Ambrx, Inc.Anti-CD3 antibody folate bioconjugates and their uses
US12144808B2 (en)2018-08-292024-11-19Intra-Cellular Therapies, Inc.Compositions and methods
CA3108553A1 (en)2018-08-312020-03-05Intra-Cellular Therapies, Inc.Novel methods
KR20210052472A (en)2018-08-312021-05-10인트라-셀룰라 써래피스, 인코퍼레이티드. New way
EP3849614B1 (en)2018-09-112023-12-20Ambrx, Inc.Interleukin-2 polypeptide conjugates and their uses
WO2020053808A1 (en)2018-09-122020-03-19Georg DewaldMethod of diagnosing vasoregulatory disorders
SG11202100935TA (en)2018-09-282021-02-25Massachusetts Inst TechnologyCollagen-localized immunomodulatory molecules and methods thereof
SG11202103275YA (en)2018-10-112021-04-29Amgen IncDownstream processing of bispecific antibody constructs
US20220009986A1 (en)2018-10-192022-01-13Ambrx, Inc.Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
EP3894440A4 (en)2018-12-132022-09-07Surface Oncology, Inc. ANTI-IL-27 ANTIBODIES AND USES THEREOF
KR20210104785A (en)2018-12-172021-08-25인트라-셀룰라 써래피스, 인코퍼레이티드. organic compounds
CN113597319A (en)2019-01-042021-11-02分解治疗有限责任公司Treatment of xerosis with nuclease fusion proteins
US11680105B2 (en)2019-01-172023-06-20Regents Of The University Of MinnesotaAntibody fragments for detecting cancer and methods of use
US11235032B2 (en)2019-01-232022-02-01Massachusetts Institute Of TechnologyCombination immunotherapy dosing regimen for immune checkpoint blockade
US11236157B2 (en)2019-01-282022-02-01Galderma Holding SATreatment of skin lesions and pruritus in prurigo nodularis patients
GB201901305D0 (en)2019-01-302019-03-20Immunocore LtdSpecific binding molecules
CN119455004A (en)2019-02-122025-02-18Ambrx公司 Compositions, methods and uses comprising antibody-TLR agonist conjugates
WO2020191305A2 (en)2019-03-202020-09-24Massachusetts Institute Of TechnologyUses of amphiphiles in immune cell therapy and compositions therefor
US12357620B2 (en)2019-03-222025-07-15New York Medical CollegeUse of rifaximin on circulating aged neutrophils in sickle cell disease
US20220220210A1 (en)2019-03-292022-07-14Chugai Seiyaku Kabushiki KaishaAnti-il-6 receptor antibody-containing inhibitor for inhibiting deterioration of bbb function
BR112021020525A2 (en)2019-04-172021-12-14Chugai Pharmaceutical Co Ltd Therapeutic agent for urological cancer that is characterized by being administered with an IL-6 inhibitor and CCR2 inhibitor in combination
CA3139850A1 (en)2019-05-102020-11-19Talengen International LimitedMethod and medicine for treating amyotrophic lateral sclerosis
EP3978018A4 (en)2019-05-312023-07-19Osaka UniversityNovel therapeutic agent for digestive organ cancer, and screening method for same
CN113905757A (en)2019-06-052022-01-07中外制药株式会社 Antibody cleavage site binding molecule
CA3140537A1 (en)2019-06-102020-12-17Takahiro IshiguroAnti-t cell antigen-binding molecule to be used in combination with cytokine inhibitor
TWI874409B (en)2019-06-132025-03-01美商安進公司Automated biomass-based perfusion control in the manufacturing of biologics
EP3990491A1 (en)2019-06-262022-05-04Massachusetts Institute of TechnologyImmunomodulatory fusion protein-metal hydroxide complexes and methods thereof
CN114072150A (en)2019-07-072022-02-18细胞内治疗公司New method
SG11202112762TA (en)2019-07-082021-12-30Amgen IncMultispecific transthyretin immunoglobulin fusions
TW202116805A (en)2019-07-102021-05-01日商中外製藥股份有限公司Claudin-6 binding molecules and uses thereof
MX2022000988A (en)2019-07-262022-05-03Amgen Inc ANTI-IL13 ANTIGEN BINDING PROTEINS.
GB201910899D0 (en)2019-07-312019-09-11Scancell LtdBinding members
GB201910900D0 (en)2019-07-312019-09-11Scancell LtdModified fc-regions to enhance functional affinity of antibodies and antigen binding fragments thereof
JP2022544236A (en)2019-08-132022-10-17アムジエン・インコーポレーテツド Interleukin-2 muteins for proliferation of regulatory T cells
GB201912657D0 (en)2019-09-032019-10-16Scancell LtdBinding members
GB201912882D0 (en)2019-09-062019-10-23Scancell LtdSsea-4 binding members
WO2021055329A1 (en)2019-09-162021-03-25Surface Oncology, Inc.Anti-cd39 antibody compositions and methods
CA3151078A1 (en)2019-09-252021-04-01Surface Oncology, Inc.Anti-il-27 antibodies and uses thereof
TW202207984A (en)2019-10-112022-03-01日商中外製藥股份有限公司Pharmaceutical composition which can be used for prevention and/or treatment of acquired hemophilia a, and product comprising said pharmaceutical composition
CA3155202A1 (en)2019-10-232021-04-29Arthur M. KriegSynthetic rig-i-like receptor agonists
WO2021081440A2 (en)2019-10-242021-04-29Minotaur Therapeutics, Inc.Chimeric cytokine modified antibodies and methods of use thereof
WO2021080682A1 (en)2019-10-242021-04-29Massachusetts Institute Of TechnologyMonoclonal antibodies that bind human cd161 and uses thereof
WO2021097344A1 (en)2019-11-132021-05-20Amgen Inc.Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
AU2020386151B2 (en)2019-11-192023-09-21MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.Novel compounds for the diagnosis, treatment and prevention of diseases associated with the aggregation of alpha-synuclein
US11753419B2 (en)2019-12-112023-09-12Intra-Cellular Therapies, Inc.4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders
MX2022007712A (en)2019-12-172022-09-26Amgen IncDual interleukin-2 /tnf receptor agonist for use in therapy.
EP3838345A1 (en)2019-12-202021-06-23Herantis Pharma OyjMacrocyclic peptides
EP3838912A1 (en)2019-12-202021-06-23Herantis Pharma OyjRetro-inverso peptides
IL294330B1 (en)2020-01-062025-07-01Vaccinex Inc Anti-CCR8 antibodies and their uses
CN115666621A (en)2020-01-132023-01-31度勒科特公司 Sustained release drug delivery system with reduced impurities and related methods
CN114867488A (en)2020-01-172022-08-05泰伦基国际有限公司 A method of treating nerve injury and related disorders
KR20220137950A (en)2020-02-062022-10-12탈렌젠 인터내셔널 리미티드 Methods and drugs for prevention and treatment of multiple sclerosis
TWI788779B (en)2020-02-112023-01-01大陸商深圳瑞健生命科學研究院有限公司 A kind of method and medicine for treating viral pneumonia
CN115551534A (en)2020-02-262022-12-30泰伦基国际有限公司Method and medicine for preventing and treating abnormal blood pressure
WO2021173889A1 (en)2020-02-262021-09-02Ambrx, Inc.Uses of anti-cd3 antibody folate bioconjugates
EP4117732A1 (en)2020-03-112023-01-18Ambrx, Inc.Interleukin-2 polypeptide conjugates and methods of use thereof
KR20220155338A (en)2020-03-192022-11-22암젠 인크 Antibodies to mucin 17 and uses thereof
JP7576861B2 (en)2020-03-242024-11-01タレンゲン インターナショナル リミテッド Methods and agents for treating Alzheimer's disease
EP4122481B1 (en)2020-03-242025-06-18Talengen International LimitedMethod and medicine for treating huntington's disease
KR20220156934A (en)2020-03-242022-11-28탈렌젠 인터내셔널 리미티드 Methods and drugs for promoting degradation of misfolded proteins and their aggregates
EP4122490A4 (en)2020-03-242023-04-05Talengen International Limited METHODS AND MEDICATIONS FOR TREATMENT OF PARKINSON'S DISEASE
JP2023106635A (en)2020-04-172023-08-02中外製薬株式会社Bispecific antigen binding molecules and compositions related thereto, uses, kits and methods for producing compositions
US20210340524A1 (en)2020-05-012021-11-04Massachusetts Institute Of TechnologyMethods for identifying chimeric antigen receptor-targeting ligands and uses thereof
WO2021221782A1 (en)2020-05-012021-11-04Massachusetts Institute Of TechnologyChimeric antigen receptor-targeting ligands and uses thereof
WO2021227417A1 (en)2020-05-112021-11-18泰伦基国际有限公司Method and drug for treating spinal muscular atrophy
EP4161520A1 (en)2020-06-052023-04-12The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David GladstoneAcvr1 (alk2) receptor inhibition to treat neurological diseases
GB202101299D0 (en)2020-06-092021-03-17Avacta Life Sciences LtdDiagnostic polypetides and methods
CN115768478A (en)2020-06-192023-03-07中外制药株式会社anti-T cell antigen binding molecules for use in combination with angiogenesis inhibitors
EP4171614A1 (en)2020-06-292023-05-03Resolve Therapeutics, LLCTreatment of sjogren's syndrome with nuclease fusion proteins
IL300225A (en)2020-07-312023-03-01Chugai Pharmaceutical Co LtdPharmaceutical composition including cell expressing chimeric receptor
WO2022023292A2 (en)2020-07-312022-02-03Friedrich-Alexander-Universität Erlangen-NürnbergCorona virus spike protein-targeting antibodies and use thereof
TW202227449A (en)2020-08-202022-07-16美商Ａｍｂｒｘ 公司Antibody-tlr agonist conjugates, methods, and uses thereof
EP4203999A1 (en)2020-08-262023-07-05Scancell LimitedNucleic acids encoding a polypeptide comprising a modified fc region of a human igg1 and at least one heterologous antigen
WO2022081436A1 (en)2020-10-152022-04-21The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesAntibody specific for sars-cov-2 receptor binding domain and therapeutic methods
WO2022087274A1 (en)2020-10-212022-04-28The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesAntibodies that neutralize type-i interferon (ifn) activity
KR20230104256A (en)2020-11-062023-07-07암젠 인크 Multitargeting bispecific antigen binding molecules of increased selectivity
JP7682567B2 (en)2020-11-172025-05-26泰▲倫▼基国▲際▼有限公司 Methods and agents for increasing NGF levels
US20240000903A1 (en)2020-11-172024-01-04Talengen International LimitedMethod and drug for increasing bdnf level
JP2024503402A (en)2021-01-122024-01-25デュレクト コーポレーション Sustained release drug delivery systems and related methods
CA3209052A1 (en)2021-02-192022-08-25Rafael Cristian CASELLASSingle domain antibodies that neutralize sars-cov-2
IL305793A (en)2021-03-122023-11-01Hoffmann La RochePharmaceutical composition for treatment or prevention of myasthenia gravis
AU2022249223A1 (en)2021-04-032023-10-12Ambrx, Inc.Anti-her2 antibody-drug conjugates and uses thereof
JP2024517759A (en)2021-04-282024-04-23ミノトール セラピューティクス インコーポレイテッド Humanized chimeric bovine antibodies and methods of use
AU2022269312A1 (en)2021-05-062023-10-19Amgen Research (Munich) GmbhCd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
AU2022270170A1 (en)2021-05-072023-09-21Surface Oncology, LLCAnti-il-27 antibodies and uses thereof
AU2022272740A1 (en)2021-05-142023-11-02Claris Biotherapeutics, Inc.Compositions of growth factor for the treatment of eye disease
US20240368272A1 (en)2021-09-032024-11-07University Of BernCompositions and methods for treating long qt syndrome
JPWO2023053282A1 (en)2021-09-292023-04-06
AU2022381918A1 (en)2021-11-032024-06-13Affimed GmbhBispecific cd16a binders
IL312060A (en)2021-11-032024-06-01Affimed Gmbh Bispecific CD16A binders
KR102707065B1 (en)2022-03-082024-09-19동국제약 주식회사Preparing method of microspheres improved suspension performance using coacervation method
WO2023203378A1 (en)2022-04-192023-10-26Garth CooperTreatment of brain copper disorders
IL316597A (en)2022-05-122024-12-01Amgen Res Munich GmbhMultichain multitargeting bispecific antigen-binding molecules of increased selectivity
US12414948B2 (en)2022-05-182025-09-16Intra-Cellular Therapies, Inc.Methods
US20250195510A1 (en)2022-05-182025-06-19Intra-Cellular Therapies, Inc.Novel methods
US20240025987A1 (en)2022-05-252024-01-25Surface Oncology, Inc.Use of anti-il-27 antibodies
US20240026001A1 (en)2022-05-252024-01-25Surface Oncology, Inc.Use of anti-il-27 antibodies
JPWO2023243689A1 (en)2022-06-162023-12-21
WO2024050526A1 (en)2022-09-022024-03-07Biomarin Pharmaceutical Inc.Compositions and methods for treating long qt syndrome
AU2023332656A1 (en)2022-09-022025-04-03Chugai Seiyaku Kabushiki KaishaTreatments for prurigo nodularis
WO2024059675A2 (en)2022-09-142024-03-21Amgen Inc.Bispecific molecule stabilizing composition
WO2024076995A1 (en)2022-10-032024-04-11Insigna Inc.Compositions for non-surgical prevention of boar taint and aggressive behavior
CN120322559A (en)2022-10-182025-07-15株式会社Nb健康研究所 Antibodies, nucleic acids, cells and drugs
CN120112307A (en)2022-11-042025-06-06泰伦基国际有限公司 A method and drug for promoting degradation of pathological TDP-43 protein
KR20250099725A (en)2022-11-042025-07-02탈렌젠 인터내셔널 리미티드 Methods and drugs for promoting the removal of pathological proteins by the ubiquitin proteasome system and the autophagy lysosome system
EP4630537A1 (en)2022-12-072025-10-15Fondazione Matilde Tettamanti e Menotti de Marchi OnlusMethods for generating genetically modified cytokine induced killer (cik) cells
CN115804830B (en)*2022-12-162024-08-20浙江圣兆药物科技股份有限公司Goserelin slow-release implant capable of shortening lag phase
CN120417904A (en)2022-12-302025-08-01细胞内治疗公司 Heterocyclic fused γ-carbolines acting on serotonin 5-HT2A receptors
WO2024173901A1 (en)2023-02-172024-08-22Intra-Cellular Therapies, Inc.Lumateperone and derivatives thereof for modulating the nervous system
WO2025006676A2 (en)2023-06-272025-01-02Firecyte Therapeutics, Inc.Insulin-like growth factor binding protein like 1 (igfbpl1) compositions and methods of use thereof
WO2025111568A1 (en)2023-11-222025-05-30Intra-Cellular Therapies, Inc.Lumateperone and analogues, as 5-ht2a or 5-ht2a/d2 receptor modulators, for use in the treatment of psychiatric disorders caused by viral, bacterial, or autoimmune encephalitis, and of psychiatric symptoms thereof
WO2025147696A1 (en)2024-01-052025-07-10Resolve Therapeutics, LlcTreatment of symptoms associated with sars-cov viral infection or a prior sars-cov viral infection with nuclease agents
WO2025155602A1 (en)2024-01-162025-07-24Genentech, Inc.Method of treating hemophilia a
WO2025191291A1 (en)2024-03-142025-09-18Universidad Complutense De MadridMethods for the prevention or treatment of erectile dysfunction (ed) by administering slpis (secretory leukocyte protease inhibitors)
WO2025198912A1 (en)2024-03-212025-09-25Hoffmann-La Roche Inc.Methods of treating myasthenia gravis

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US3887699A (en)*1969-03-241975-06-03Seymour YollesBiodegradable polymeric article for dispensing drugs
US3773919A (en)*1969-10-231973-11-20Du PontPolylactide-drug mixtures
US3839297A (en)*1971-11-221974-10-01Ethicon IncUse of stannous octoate catalyst in the manufacture of l(-)lactide-glycolide copolymer sutures
JPS5324423B2 (en)*1972-04-291978-07-20
JPS5017525A (en)*1973-06-141975-02-24
JPS5749532B2 (en)*1974-03-191982-10-22
JPS5035158A (en)*1973-07-241975-04-03
JPS5314072B2 (en)*1973-09-291978-05-15
JPS5726506B2 (en)*1974-03-081982-06-04
US3976071A (en)*1974-01-071976-08-24Dynatech CorporationMethods of improving control of release rates and products useful in same
NZ181036A (en)*1975-06-121978-12-18A SchallyLuteinising hormone releasing hormone analogues and intermediates therefor
US4010196A (en)*1975-06-251977-03-01American Home Products CorporationLinear polyester salts
US4011312A (en)*1975-06-251977-03-08American Home Products CorporationProlonged release drug form for the treatment of bovine mastitis
CA1123984A (en)*1977-11-161982-05-18Yuzi OkuzumiBlock copolymers of lactide and glycolide and surgical prosthesis therefrom
US4234571A (en)*1979-06-111980-11-18Syntex (U.S.A.) Inc.Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone
US4273920A (en)*1979-09-121981-06-16Eli Lilly And CompanyPolymerization process and product
US4333919A (en)*1979-09-121982-06-08Eli Lilly And CompanyGrowth promotant controlled release formulations and method of treatment
US4331652A (en)*1979-09-121982-05-25Eli Lilly And CompanyControlled release parasitic formulations and method
US4293539A (en)*1979-09-121981-10-06Eli Lilly And CompanyControlled release formulations and method of treatment
PH17900A (en)*1979-09-121985-01-25Lilly Co EliGrowth promotant controlled release formulations and method of treatment
PH19942A (en)*1980-11-181986-08-14Sintex IncMicroencapsulation of water soluble polypeptides
IE52535B1 (en)*1981-02-161987-12-09Ici PlcContinuous release pharmaceutical compositions

Also Published As

Publication numberPublication date
HK107890A (en)1990-12-28
FI820467L (en)1982-08-17
NZ199732A (en)1985-08-30
AU2840789A (en)1989-05-04
MY101545A (en)1991-12-17
EP0058481A1 (en)1982-08-25
NO162103C (en)1992-03-04
JPH0686390B2 (en)1994-11-02
HU199695B (en)1990-03-28
JPS57150609A (en)1982-09-17
US4767628A (en)1988-08-30
GR76791B (en)1984-09-04
DE3273501D1 (en)1986-11-06
JPH05221871A (en)1993-08-31
JPH0774143B2 (en)1995-08-09
ES8307845A1 (en)1983-08-01
ATE22535T1 (en)1986-10-15
IE52535B1 (en)1987-12-09
IE820165L (en)1982-08-16
FI80594B (en)1990-03-30
HU186904B (en)1985-10-28
JPS6264824A (en)1987-03-23
JPH05271051A (en)1993-10-19
NO820433L (en)1982-08-17
DK164845B (en)1992-08-31
US5004602A (en)1991-04-02
AU602623B2 (en)1990-10-18
YU31582A (en)1985-04-30
US4767628B1 (en)1990-07-17
PT74434A (en)1982-03-01
EP0058481B1 (en)1986-10-01
ES509647A0 (en)1983-08-01
CA1169090A (en)1984-06-12
AU7998682A (en)1982-08-26
NO162103B (en)1989-07-31
AU6498886A (en)1987-02-19
JPH0157098B2 (en)1989-12-04
AU582920B2 (en)1989-04-13
DK59182A (en)1982-08-17
AU560829B2 (en)1987-04-16
YU44066B (en)1990-02-28
EP0058481B2 (en)2003-05-21
JPH031330B2 (en)1991-01-10
ZA82565B (en)1982-10-27

Similar Documents

PublicationPublication DateTitle
US4767628B1 (en)
ES2009346A6 (en) PROCEDURE FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS CONTAINING HYDROINSOLUBLE POLYPEPTIDES.
DE69000881D1 (en) MEDICINE PREPARATION CONTAINING 2-PROPYLVALERIC ACID WITH DELAYED RELEASE OF THE ACTIVE SUBSTANCE.
DE3486409D1 (en) Composition for the controlled release of an active ingredient.
HUT45850A (en)Insecticides comprising azolinone derivatives as active ingredient and process for producing the active ingredients
IL90551A0 (en)Stable,injectable,aqueous pharmaceutical compositions for the treatment of cardiac conditions
ES8102141A1 (en)3,7-Disubstituted-3-cephem-4-carboxylic acid compounds
HUT48217A (en)Pesticides comprising 5-methylamino-1-arylpyrazole derivatives as active ingredient and process for producing the active ingredients
ZA884622B (en)Pharmaceutical compositions in the form of pellets with enzymatically controlled release of the pharmaceutical,substance
ATE68686T1 (en) SYSTEM FOR RELEASING SUBSTANCES IN THE VAGINA.
HUT47233A (en)Process for producing pharmaceutical comprising phenol derivatives as active ingredient and for producing the active ingredients
HUT49596A (en)Herbicides comprising iminophenylthiazolidine derivatives as actie ingredient and process for producing the active ingredients
GR3007995T3 (en)
HUT48096A (en)Insecticides comprising 2-imino-1,3-dithiethane derivatives as active ingredient and process for producing the active ingredients
IT8721687A0 (en) DERIVATIVES OF THE OXYME OF 1,2,5,6-TETRAHYDROPYRIDIN-3-CARBOXA LDEHYDE, THEIR PREPARATION PROCEDURE AND THEIR USE AS MEDICINAL SUBSTANCES.
FI880210L (en) The method produces an oral stabilized, slow and controlled release pharmaceutical preparation of the active ingredient
HUT47397A (en)Herbicides comprising sulfonyl-amino-guanidino-azine derivatives as active ingredient and process for producing the active ingredients
JPS6442470A (en)Guanidinecarboxylic acid esters, manufacture and medicinal composition
HUT49855A (en)Insecticides and nematocides comprising 5-ethylamino-1-arylpyrazole derivatives as active ingredient and process for producing the active ingredients
HUT47540A (en)Herbicides comprising 1-phenyl-5-exomethylene-pyrrolidin-2-one derivatives as active ingredient and process for producing the active ingredients
HUT47240A (en)Insecticides and acaricides comprising benzoyl-urea derivatives as active ingredient and process for producing the active ingredients
DK45592A (en) POLY (LACTID-CO-GLYCOLID) POLYMER CONTAINING AT LEAST 25 MOL% Lactic Acid UNITS AND UP TO 75 MOL% GLYCOS ACID UNITS AND PROCEDURES FOR PREPARING IT
IT8520736A0 (en) MEDICINAL COMPOSITION AND METHOD FOR THE TREATMENT OF PERIARTHRITIS AND SIMILAR DISEASES.
HUT46643A (en)Process for producing styryl ketones and pharmaceutical compositions comprising the same as active ingredient
GR871546B (en)Orthopaedic manufacture destined to lean the human arm more easy and safe

Legal Events

DateCodeTitleDescription
PC3ATransfer or assignment

Free format text:940929 ZENECA LIMITED GB
[8]ページ先頭
©2009-2025 Movatter.jp